{"PMC6163780": [], "f5a7c09f428bba88830110ed18b0f2a078728732": [["Loneliness, another emerging health crisis, particularly impacts the Western world, with severe health consequences.", [["Loneliness", "DISEASE", 0, 10]]], ["(6) These include diabetes, dementia, and heart disease with a risk approximating that of smoking 15 cigarettes/day.", [["heart", "ANATOMY", 42, 47], ["diabetes", "DISEASE", 18, 26], ["dementia", "DISEASE", 28, 36], ["heart disease", "DISEASE", 42, 55], ["smoking", "CHEMICAL", 90, 97], ["heart", "ORGAN", 42, 47], ["diabetes", "PROBLEM", 18, 26], ["dementia", "PROBLEM", 28, 36], ["heart disease", "PROBLEM", 42, 55], ["diabetes", "OBSERVATION", 18, 26], ["dementia", "OBSERVATION", 28, 36], ["heart", "ANATOMY", 42, 47], ["disease", "OBSERVATION", 48, 55]]], ["(7) Loneliness exacerbates mental health and substance use issues, including psychosis and suicide.", [["psychosis", "DISEASE", 77, 86], ["psychosis", "PROBLEM", 77, 86], ["suicide", "PROBLEM", 91, 98]]], ["(7, 8) Health care utilization is far greater for individuals over 60 experiencing loneliness, escalating the cost to the health care system as individuals seek social contact through clinician visits.", [["loneliness", "DISEASE", 83, 93]]], ["(9) Approximately 42 Million Americans suffer from loneliness, which significantly worsened across the country as the COVID-19 pandemic forced more Americans to stay at home.(9) Most continue to rightfully shelter in place when possible, and others have rigid restrictions imposed on those who may come to visit them.", [["loneliness", "DISEASE", 51, 61], ["loneliness", "PROBLEM", 51, 61]]], ["Individuals confined to congregant settings: nursing home residents, hospitalized patients and those incarcerated have regulations preventing their loved ones from visiting and often isolating them from anyone else in the facility.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["Even individuals with a wealth of friendships or family around them may suffer from the subjective experience of loneliness, due in part to a need for presence, empathic understanding, and lack of experience in perspective taking.", [["loneliness", "DISEASE", 113, 123]]], ["(10) Not surprisingly, people experiencing homelessness, poverty, and healthcare disparities are at increased risk to suffer from one or more of these healthcare crises.", [["homelessness", "DISEASE", 43, 55], ["poverty", "DISEASE", 57, 64], ["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29]]], ["Zoom, to sign on from the comfort of their living room for a primary care, chronic pain or mental health appointment.", [["pain", "DISEASE", 83, 87], ["chronic pain", "PROBLEM", 75, 87]]], ["So the very patients that we are most concerned about-the impoverished, people of color, marginalized populations and those experiencing homelessness and racial health inequities-do not get to experience these new connection points to the same extent.", [["homelessness", "DISEASE", 137, 149], ["patients", "ORGANISM", 12, 20], ["people", "ORGANISM", 72, 78], ["patients", "SPECIES", 12, 20], ["people", "SPECIES", 72, 78]]], ["(23) We desperately need a national strategy to stop the community spread of the COVID-19", [["COVID-19", "CHEMICAL", 81, 89], ["COVID-19", "DNA", 81, 89], ["a national strategy", "TREATMENT", 25, 44], ["the COVID", "TEST", 77, 86]]]], "PMC7194518": [["IntroductionCoronavirus disease 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) that emerged out of Wuhan, China in late 2019.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["viral illness", "DISEASE", 53, 66], ["acute respiratory syndrome coronavirus", "DISEASE", 88, 126], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 81, 126], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a viral illness", "PROBLEM", 51, 66], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 77, 126], ["viral illness", "OBSERVATION", 53, 66], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114]]], ["Since its emergence, COVID-19 has spread to over 100 countries, sickening about 170,000 people and killing about 6500 as of March 16th, 2020 [1].", [["COVID-19", "CHEMICAL", 21, 29], ["COVID-19", "CELL", 21, 29], ["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["COVID", "TEST", 21, 26]]], ["COVID-19 is characterized by fevers, malaise, and dry cough which can progress to pneumonia.", [["fevers", "DISEASE", 29, 35], ["dry cough", "DISEASE", 50, 59], ["pneumonia", "DISEASE", 82, 91], ["COVID", "TEST", 0, 5], ["fevers", "PROBLEM", 29, 35], ["malaise", "PROBLEM", 37, 44], ["dry cough", "PROBLEM", 50, 59], ["pneumonia", "PROBLEM", 82, 91], ["fevers", "OBSERVATION", 29, 35], ["malaise", "OBSERVATION", 37, 44], ["dry", "OBSERVATION_MODIFIER", 50, 53], ["cough", "OBSERVATION", 54, 59], ["pneumonia", "OBSERVATION", 82, 91]]], ["It is significantly more infectious and pathogenic than seasonal flu, with an estimated case fatality rate of 0.5\u20133% and approximately 5% of diagnosed patients requiring critical care [2,3].", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["pathogenic", "PROBLEM", 40, 50], ["seasonal flu", "PROBLEM", 56, 68], ["fatality rate", "TEST", 93, 106], ["significantly", "OBSERVATION_MODIFIER", 6, 19], ["more", "OBSERVATION_MODIFIER", 20, 24], ["infectious", "OBSERVATION", 25, 35]]], ["Disease severity is associated with advanced age and comorbidities [4,5].", [["Disease severity", "PROBLEM", 0, 16], ["advanced age and comorbidities", "PROBLEM", 36, 66]]], ["Regions heavily affected, including northern Italy and Wuhan, China, have faced significant challenges to health system capacity, particularly with respect to intensive care.", [["intensive care", "TREATMENT", 159, 173], ["heavily", "OBSERVATION_MODIFIER", 8, 15], ["affected", "OBSERVATION", 16, 24]]], ["At present, sustained community transmission of COVID-19 is occurring in many areas worldwide, including the United States.", [["COVID-19", "CHEMICAL", 48, 56], ["COVID", "TEST", 48, 53]]], ["Public health efforts are oriented towards mitigation and limiting the rate of spread to prevent overextension of available healthcare resources such as ventilators [3].IntroductionThe COVID-19 pandemic occurs in the broader context of increasing emerging infectious disease burden.", [["infectious disease", "DISEASE", 256, 274], ["The COVID", "TREATMENT", 181, 190], ["increasing emerging infectious disease burden", "PROBLEM", 236, 281], ["increasing", "OBSERVATION_MODIFIER", 236, 246], ["infectious", "OBSERVATION", 256, 266]]], ["After a decline in infectious disease morbidity and mortality in the early and mid-20th century due to antibiotics, vaccines, and modern sanitation, the threat of infectious diseases has resurfaced [6,7].", [["infectious disease", "DISEASE", 19, 37], ["infectious diseases", "DISEASE", 163, 182], ["a decline in infectious disease morbidity", "PROBLEM", 6, 47], ["antibiotics", "TREATMENT", 103, 114], ["vaccines", "TREATMENT", 116, 124], ["modern sanitation", "TREATMENT", 130, 147], ["infectious diseases", "PROBLEM", 163, 182], ["decline", "OBSERVATION_MODIFIER", 8, 15], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["infectious", "OBSERVATION", 163, 173]]], ["In addition to newly antibiotic-resistant organisms, new infections with epidemic or pandemic potential have been appearing steadily over the past several decades, including Ebola Virus Disease, HIV disease, avian influenza, severe acute respiratory syndrome, Zika virus, and many others.", [["infections", "DISEASE", 57, 67], ["Ebola Virus Disease", "DISEASE", 174, 193], ["HIV disease", "DISEASE", 195, 206], ["avian influenza", "DISEASE", 208, 223], ["acute respiratory syndrome, Zika virus", "DISEASE", 232, 270], ["Ebola Virus", "ORGANISM", 174, 185], ["avian influenza", "ORGANISM", 208, 223], ["Ebola Virus", "SPECIES", 174, 185], ["HIV", "SPECIES", 195, 198], ["avian influenza", "SPECIES", 208, 223], ["Zika virus", "SPECIES", 260, 270], ["Ebola Virus", "SPECIES", 174, 185], ["HIV", "SPECIES", 195, 198], ["severe acute respiratory syndrome, Zika virus", "SPECIES", 225, 270], ["newly antibiotic", "TREATMENT", 15, 31], ["resistant organisms", "PROBLEM", 32, 51], ["new infections", "PROBLEM", 53, 67], ["epidemic", "PROBLEM", 73, 81], ["Ebola Virus Disease", "PROBLEM", 174, 193], ["HIV disease", "PROBLEM", 195, 206], ["avian influenza", "PROBLEM", 208, 223], ["severe acute respiratory syndrome", "PROBLEM", 225, 258], ["Zika virus", "PROBLEM", 260, 270], ["resistant organisms", "OBSERVATION", 32, 51], ["new", "OBSERVATION_MODIFIER", 53, 56], ["infections", "OBSERVATION", 57, 67], ["steadily", "OBSERVATION_MODIFIER", 124, 132], ["Ebola Virus Disease", "OBSERVATION", 174, 193], ["HIV disease", "OBSERVATION", 195, 206], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["respiratory syndrome", "OBSERVATION", 238, 258], ["Zika virus", "OBSERVATION", 260, 270]]], ["Fueled by the increasing speed and scope of global travel, the changing interface between humans and animals, climate change, and socioeconomic disparities, the threat of new epidemics and pandemics has been recognized as one of the great public health challenges of the 21st century [8,9].IntroductionWhile much of the early scholarly work on COVID-19 has focused on intensive care, emergency care, and primary care, prior emerging infectious disease epidemics have demonstrated that the role of mental health clinicians is key on multiple levels.", [["pandemics", "DISEASE", 189, 198], ["infectious disease epidemics", "DISEASE", 433, 461], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["socioeconomic disparities", "PROBLEM", 130, 155], ["new epidemics", "PROBLEM", 171, 184], ["pandemics", "PROBLEM", 189, 198], ["emergency care", "TREATMENT", 384, 398], ["new", "OBSERVATION_MODIFIER", 171, 174], ["epidemics", "OBSERVATION", 175, 184]]], ["Given the unprecedented scope of COVID-19, operationalizing the potential roles of psychiatrists in general, and CL psychiatrists in particular, is essential for a coordinated response.", [["CL", "MULTI-TISSUE_STRUCTURE", 113, 115], ["COVID", "TEST", 33, 38]]], ["Here we set out potential key roles of CL psychiatrists in the context of COVID-19 and future epidemic/pandemic scenarios, and use our experience at a COVID-affected medical center to identify and problem-solve challenges in filling those roles.Patient care ::: Roles for the CL psychiatrist in the COVID-19 pandemicIn the epidemic/pandemic context, mental health clinicians need to tailor their patient care in several ways.", [["CL", "MULTI-TISSUE_STRUCTURE", 39, 41], ["patient", "ORGANISM", 396, 403], ["Patient", "SPECIES", 245, 252], ["patient", "SPECIES", 396, 403], ["COVID", "TEST", 74, 79]]], ["Perhaps most acutely, for patients affected by COVID-19, our ability to control mental health comorbidities and manage behavioral agitation in conditions like delirium may be key for maximizing the number of patients able to receive high quality medical care.", [["behavioral agitation", "DISEASE", 119, 139], ["delirium", "DISEASE", 159, 167], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 208, 216], ["COVID", "TEST", 47, 52], ["mental health comorbidities", "PROBLEM", 80, 107], ["behavioral agitation", "PROBLEM", 119, 139], ["delirium", "PROBLEM", 159, 167], ["high quality medical care", "TREATMENT", 233, 258]]], ["Patients in the ICU or hospital ward setting who are behaviorally dysregulated require disproportionately high workforce and resource investments.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["behaviorally dysregulated", "PROBLEM", 53, 78], ["resource investments", "TREATMENT", 125, 145]]], ["In epidemic scenarios, poorly managed psychotic or delirious patients may literally preclude stretched-thin staff from caring for other people in need.", [["psychotic", "DISEASE", 38, 47], ["delirious", "DISEASE", 51, 60], ["patients", "ORGANISM", 61, 69], ["people", "ORGANISM", 136, 142], ["patients", "SPECIES", 61, 69], ["people", "SPECIES", 136, 142], ["delirious", "PROBLEM", 51, 60]]], ["Aggressive management of behavioral dysregulation and high-quality care of underlying psychiatric disorders even in the setting of comorbid infection is key to improving both individual and communal outcomes.", [["psychiatric disorders", "DISEASE", 86, 107], ["infection", "DISEASE", 140, 149], ["Aggressive management", "TREATMENT", 0, 21], ["behavioral dysregulation", "PROBLEM", 25, 49], ["underlying psychiatric disorders", "PROBLEM", 75, 107], ["comorbid infection", "PROBLEM", 131, 149], ["behavioral dysregulation", "OBSERVATION", 25, 49], ["infection", "OBSERVATION", 140, 149]]], ["To minimize exposure and mitigate the loss of workforce to quarantines, psychiatric consultation can be done through video platforms as well as in person.Patient care ::: Roles for the CL psychiatrist in the COVID-19 pandemicBeyond the risks of behavioral dysregulation within a thinly stretched system, clinicians should also be astute about the social and psychological impact of being infected with a potentially lethal epidemic illness.", [["psychiatric", "DISEASE", 72, 83], ["behavioral dysregulation", "DISEASE", 245, 269], ["CL", "MULTI-TISSUE_STRUCTURE", 185, 187], ["person", "SPECIES", 147, 153], ["Patient", "SPECIES", 154, 161], ["behavioral dysregulation", "PROBLEM", 245, 269], ["a potentially lethal epidemic illness", "PROBLEM", 402, 439]]], ["During the Ebola outbreak of 2018, patients under treatment were noted to have significant distress from the effects of isolation, the fear of dying (especially as other patients perished from the illness), and the sense of social rejection.", [["Ebola", "DISEASE", 11, 16], ["illness", "DISEASE", 197, 204], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 170, 178], ["treatment", "TREATMENT", 50, 59], ["significant distress", "PROBLEM", 79, 99], ["isolation", "TREATMENT", 120, 129], ["social rejection", "PROBLEM", 224, 240], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["distress", "OBSERVATION", 91, 99], ["social rejection", "OBSERVATION", 224, 240]]], ["In the Ebola treatment center in Beni, Democratic Republic of Congo, in 2018, patients were visited by psychologists multiple times daily to help mitigate distress [10].", [["Ebola", "DISEASE", 7, 12], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["distress", "PROBLEM", 155, 163]]], ["This distress may be exacerbated by effects of quarantine, which may in itself may be associated with trauma-related disorders, stress, anger, and mood dysregulation [11].", [["trauma", "DISEASE", 102, 108], ["stress, anger", "DISEASE", 128, 141], ["mood dysregulation", "DISEASE", 147, 165], ["This distress", "PROBLEM", 0, 13], ["quarantine", "TREATMENT", 47, 57], ["trauma", "PROBLEM", 102, 108], ["related disorders", "PROBLEM", 109, 126], ["stress, anger", "PROBLEM", 128, 141], ["mood dysregulation", "PROBLEM", 147, 165]]], ["Psychiatrists should work with the broader healthcare team to ensure infected and quarantined patients have access to appropriate mental health screening and treatment.Patient care ::: Roles for the CL psychiatrist in the COVID-19 pandemicPandemics/epidemics may cause collective fear and impose lifestyle changes for all patients, not only those directly impacted by infection.", [["infection", "DISEASE", 368, 377], ["patients", "ORGANISM", 94, 102], ["CL", "MULTI-TISSUE_STRUCTURE", 199, 201], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 94, 102], ["Patient", "SPECIES", 168, 175], ["patients", "SPECIES", 322, 330], ["appropriate mental health screening", "TEST", 118, 153], ["treatment", "TREATMENT", 158, 167], ["collective fear", "PROBLEM", 269, 284], ["infection", "PROBLEM", 368, 377], ["infected", "OBSERVATION", 69, 77], ["infection", "OBSERVATION", 368, 377]]], ["Many of our uninfected patients are struggling with concerns related to infection risk.", [["infection", "DISEASE", 72, 81], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["infection risk", "PROBLEM", 72, 86], ["infection", "OBSERVATION", 72, 81]]], ["Our medically morbid patients in the CL setting may be especially frightened because of their potentially greater risk for mortality and because of the specter of rationed care that emerges in epidemic/pandemic scenarios.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["During the Ebola epidemic, mental health professionals even beyond those caring for Ebola patients directly reported overwhelming MH need because of issues like grief and anxiety [12].", [["Ebola", "DISEASE", 11, 16], ["Ebola", "DISEASE", 84, 89], ["MH", "DISEASE", 130, 132], ["grief", "DISEASE", 161, 166], ["anxiety", "DISEASE", 171, 178], ["Ebola", "ORGANISM", 84, 89], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["grief", "PROBLEM", 161, 166], ["anxiety", "PROBLEM", 171, 178]]], ["Of note, many of the patients we care for in the CL psychiatry setting, including patients with comorbid mental/physical illness, elderly patients, and patients with serious mental illness (SMI), are particularly vulnerable to changes in access to care that may occur during pandemics; psychiatrists in various settings should be aware and actively trying to mitigate lost access to care for high risk patients, while taking steps to avoid risking perpetuation of infection [13].Advocacy ::: Roles for the CL psychiatrist in the COVID-19 pandemicEven under normal circumstances, psychiatrists are accustomed to advocating for patients and conditions subject to significant stigma.", [["comorbid mental/physical illness", "DISEASE", 96, 128], ["SMI", "DISEASE", 190, 193], ["infection", "DISEASE", 464, 473], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 402, 410], ["CL", "MULTI-TISSUE_STRUCTURE", 506, 508], ["patients", "ORGANISM", 626, 634], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 402, 410], ["patients", "SPECIES", 626, 634], ["comorbid mental/physical illness", "PROBLEM", 96, 128], ["serious mental illness", "PROBLEM", 166, 188], ["infection", "PROBLEM", 464, 473], ["significant stigma", "PROBLEM", 661, 679], ["infection", "OBSERVATION", 464, 473], ["significant", "OBSERVATION_MODIFIER", 661, 672], ["stigma", "OBSERVATION", 673, 679]]], ["CL psychiatrists must routinely navigate stigma against their patients or against psychiatric illness more broadly among patients, the lay public, and fellow non-psychiatrist clinicians.", [["psychiatric illness", "DISEASE", 82, 101], ["CL", "MULTI-TISSUE_STRUCTURE", 0, 2], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 121, 129]]], ["Historically, epidemics have resulted in high levels of blame and stigmatization of groups assigned responsibility [7].", [["epidemics", "PROBLEM", 14, 23]]], ["Humanizing patients and utilizing sound, science-based information are means of preventing negative outcomes for patients stemming from fear and/or stigma.Advocacy ::: Roles for the CL psychiatrist in the COVID-19 pandemicFurthermore, patients with comorbid mental and physical illness may be the most vulnerable to the social and biological effects of the pandemic.", [["comorbid mental and physical illness", "DISEASE", 249, 285], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 235, 243], ["Humanizing patients", "TREATMENT", 0, 19], ["fear", "PROBLEM", 136, 140], ["stigma", "PROBLEM", 148, 154], ["comorbid mental and physical illness", "PROBLEM", 249, 285]]], ["Many of these patients are homeless and living in spaces conducive to rapid disease spread [15].", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["rapid disease spread", "PROBLEM", 70, 90]]], ["Understanding the needs of our most vulnerable patients and helping to see that those needs are met in safe ways should be a key part of our work during pandemics.Advocacy ::: Roles for the CL psychiatrist in the COVID-19 pandemicFinally, psychiatrists may have something to offer more broadly in the battle against misinformation.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["Social media enables rapid dissemination of misinformation and there are global funding deficits for public health communication [14].", [["global funding deficits", "PROBLEM", 73, 96]]], ["Patients encountered by CL psychiatrists, including individuals with cognitive or psychiatric disorders, may be especially vulnerable to misinformation.", [["cognitive or psychiatric disorders", "DISEASE", 69, 103], ["Patients", "ORGANISM", 0, 8], ["CL", "MULTI-TISSUE_STRUCTURE", 24, 26], ["Patients", "SPECIES", 0, 8], ["cognitive or psychiatric disorders", "PROBLEM", 69, 103]]], ["Disseminating correct information to our professional and personal communities in an effective, psychologically astute way is of the utmost importance.Scholarship ::: Roles for the CL psychiatrist in the COVID-19 pandemicIt may not be self-evident to most clinicians that an infectious disease that does not primarily target the brain and nervous system may have psychiatric sequelae.", [["brain", "ANATOMY", 329, 334], ["nervous system", "ANATOMY", 339, 353], ["infectious disease", "DISEASE", 275, 293], ["psychiatric", "DISEASE", 363, 374], ["CL", "MULTI-TISSUE_STRUCTURE", 181, 183], ["brain", "ORGAN", 329, 334], ["nervous system", "ANATOMICAL_SYSTEM", 339, 353], ["an infectious disease", "PROBLEM", 272, 293], ["psychiatric sequelae", "PROBLEM", 363, 383], ["infectious", "OBSERVATION", 275, 285], ["brain", "ANATOMY", 329, 334], ["nervous system", "ANATOMY", 339, 353]]], ["Early research on emerging pathogens may exclude study of the acute and long-term psychiatric effects of the illness.", [["psychiatric", "DISEASE", 82, 93], ["illness", "DISEASE", 109, 116], ["emerging pathogens", "PROBLEM", 18, 36], ["the acute and long-term psychiatric effects", "PROBLEM", 58, 101], ["the illness", "PROBLEM", 105, 116], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["long-term", "OBSERVATION_MODIFIER", 72, 81]]], ["Proactively instituting cross-institutional research-oriented data-sharing about the psychiatric dimensions of new pathogens is imperative for providing high quality care to acutely ill patients, survivors, and caregivers.Scholarship ::: Roles for the CL psychiatrist in the COVID-19 pandemicMany recent emerging infectious diseases, including Ebola, HIV/AIDS, and Zika, have had neuropsychiatric sequelae.", [["psychiatric", "DISEASE", 85, 96], ["acutely ill", "DISEASE", 174, 185], ["infectious diseases", "DISEASE", 313, 332], ["Ebola, HIV/AIDS", "DISEASE", 344, 359], ["Zika", "DISEASE", 365, 369], ["patients", "ORGANISM", 186, 194], ["Ebola", "ORGANISM", 344, 349], ["patients", "SPECIES", 186, 194], ["Ebola", "SPECIES", 344, 349], ["HIV", "SPECIES", 351, 354], ["HIV", "SPECIES", 351, 354], ["new pathogens", "PROBLEM", 111, 124], ["Ebola", "PROBLEM", 344, 349], ["HIV", "PROBLEM", 351, 354], ["AIDS", "PROBLEM", 355, 359], ["Zika", "PROBLEM", 365, 369], ["neuropsychiatric sequelae", "PROBLEM", 380, 405], ["infectious", "OBSERVATION", 313, 323]]], ["Although no virus-mediated neuropsychiatric syndromes have yet been described from COVID-19, the absence of such syndromes has not been confirmed.", [["neuropsychiatric syndromes", "DISEASE", 27, 53], ["COVID-19", "CELL", 83, 91], ["virus-mediated neuropsychiatric syndromes", "PROBLEM", 12, 53], ["COVID", "TEST", 83, 88], ["such syndromes", "PROBLEM", 108, 122], ["no", "UNCERTAINTY", 9, 11], ["virus", "OBSERVATION", 12, 17]]], ["Furthermore, there is evidence that the SARS-Cov-2 virus may target the CNS [16].", [["CNS", "ANATOMY", 72, 75], ["SARS-Cov-2 virus", "ORGANISM", 40, 56], ["SARS-Cov-2 virus", "SPECIES", 40, 56], ["the SARS-Cov-2 virus", "PROBLEM", 36, 56]]], ["Identifying and understanding neuropsychiatric manifestations of novel pathogens is an important role for consulting psychiatrists, many of whom may recognize subtle symptoms or patterns overlooked by non-psychiatric clinicians.", [["subtle symptoms", "PROBLEM", 159, 174]]], ["To that end, operationalized ways of collecting data on consultations provided to patients with emerging infections should be created and shared across institutions for rapid pattern identification and data consolidation.Scholarship ::: Roles for the CL psychiatrist in the COVID-19 pandemicPrior epidemics including HIV, SARS and Ebola have been associated with long term MH complications among families and surviving patients [12,17].", [["infections", "DISEASE", 105, 115], ["HIV, SARS and Ebola", "DISEASE", 317, 336], ["patients", "ORGANISM", 82, 90], ["CL", "MULTI-TISSUE_STRUCTURE", 251, 253], ["HIV", "ORGANISM", 317, 320], ["Ebola", "ORGANISM", 331, 336], ["patients", "ORGANISM", 419, 427], ["patients", "SPECIES", 82, 90], ["HIV", "SPECIES", 317, 320], ["patients", "SPECIES", 419, 427], ["HIV", "SPECIES", 317, 320], ["emerging infections", "PROBLEM", 96, 115], ["rapid pattern identification", "TEST", 169, 197], ["data consolidation", "PROBLEM", 202, 220], ["HIV", "PROBLEM", 317, 320], ["long term MH complications", "PROBLEM", 363, 389], ["infections", "OBSERVATION", 105, 115], ["consolidation", "OBSERVATION", 207, 220]]], ["Such complications are often multifactorial and may include biological sequelae of the infection, trauma and grief, social stigma, and isolation.", [["infection", "DISEASE", 87, 96], ["trauma", "DISEASE", 98, 104], ["grief", "DISEASE", 109, 114], ["Such complications", "PROBLEM", 0, 18], ["the infection", "PROBLEM", 83, 96], ["trauma", "PROBLEM", 98, 104], ["grief", "PROBLEM", 109, 114], ["isolation", "TREATMENT", 135, 144], ["infection", "OBSERVATION", 87, 96]]], ["Studying the vulnerabilities of patients and caregivers following infection and creating evidence-based screening and treatment approaches is a mandate for psychiatrists.Supporting our colleagues ::: Roles for the CL psychiatrist in the COVID-19 pandemicData from frontline healthcare workers in the early HIV epidemic, SARS, Ebola, and other epidemics demonstrates that working at the frontline of a pandemic/epidemic has significant psychiatric repercussions including burnout, anxiety and post-traumatic stress disorder [12,18].", [["infection", "DISEASE", 66, 75], ["HIV epidemic", "DISEASE", 306, 318], ["SARS", "DISEASE", 320, 324], ["Ebola", "DISEASE", 326, 331], ["psychiatric", "DISEASE", 435, 446], ["burnout", "DISEASE", 471, 478], ["anxiety", "DISEASE", 480, 487], ["post-traumatic stress disorder", "DISEASE", 492, 522], ["patients", "ORGANISM", 32, 40], ["CL", "MULTI-TISSUE_STRUCTURE", 214, 216], ["patients", "SPECIES", 32, 40], ["HIV", "SPECIES", 306, 309], ["HIV", "SPECIES", 306, 309], ["infection", "PROBLEM", 66, 75], ["based screening", "TEST", 98, 113], ["treatment approaches", "TREATMENT", 118, 138], ["SARS", "PROBLEM", 320, 324], ["burnout", "PROBLEM", 471, 478], ["anxiety", "PROBLEM", 480, 487], ["post-traumatic stress disorder", "PROBLEM", 492, 522]]], ["The etiology of these disorders is multifactorial and includes fear of infection or death of self or family, sense of lack of control, sense of inability to help patients in situations of limited resources, moral injury in situations of rationing, distrust of institutional responses, and social stigma due to exposure.Supporting our colleagues ::: Roles for the CL psychiatrist in the COVID-19 pandemicIn Wuhan, preliminary data on frontline healthcare providers showed high burdens of depressive and anxiety symptoms.", [["infection", "DISEASE", 71, 80], ["death", "DISEASE", 84, 89], ["depressive", "DISEASE", 487, 497], ["anxiety", "DISEASE", 502, 509], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["these disorders", "PROBLEM", 16, 31], ["infection", "PROBLEM", 71, 80], ["death", "PROBLEM", 84, 89], ["moral injury", "PROBLEM", 207, 219], ["depressive and anxiety symptoms", "PROBLEM", 487, 518], ["infection", "OBSERVATION", 71, 80]]], ["Mental health services were established for health care providers at the frontline of caring for COVID-19 patients including online interventions, a phone hotline, and group activities.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["online interventions", "TREATMENT", 125, 145]]], ["Interviews with staff demonstrated that worry about infecting family and difficulties dealing with uncooperative patients are particularly challenging areas.", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121]]], ["Training was established for dealing with uncooperative patients.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Other interventions included the presence of mental health clinicians on premises available to staff as needed [19].Supporting our colleagues ::: Roles for the CL psychiatrist in the COVID-19 pandemicData from the H1N1 influenza epidemic in Japan in 2009 showed that institutional trust was correlated with motivation to work at the frontline.", [["influenza", "DISEASE", 219, 228], ["CL", "MULTI-TISSUE_STRUCTURE", 160, 162], ["H1N1 influenza", "SPECIES", 214, 228], ["the H1N1 influenza epidemic", "PROBLEM", 210, 237]]], ["Experience from prior epidemics and from the Wuhan response suggests that psychiatrists can engender feelings of institutional trust by demonstrations of genuine support for our colleagues wellbeing and mental health [20].", [["genuine support", "TREATMENT", 154, 169]]], ["Such work is contingent on availability, but also on willingness to move beyond the traditional treatment frame to engage with clinicians on the frontline in informal ways, and to move beyond the traditional mental health treatment paradigm to address social and health-related concerns like housing and risk to family.Supporting the system ::: Roles for the CL psychiatrist in the COVID-19 pandemicCL psychiatrists are accustomed to formulating clinical problems in terms of a variety of systems, levels of system organization, and interactions between systems, depending on which formulation will yield the most fruitful intervention.", [["fruitful intervention", "TREATMENT", 614, 635]]], ["For example, we may focus in one case on metabolic derangements (organ systems), and in another on interpersonal conflicts (social systems) as of etiologic relevance and as targets for intervention.", [["organ", "ANATOMY", 65, 70], ["metabolic derangements", "DISEASE", 41, 63], ["organ", "ORGAN", 65, 70], ["intervention", "TREATMENT", 185, 197]]], ["Pandemic infectious disease stresses systems across a variety of domains.", [["infectious disease", "DISEASE", 9, 27], ["Pandemic infectious disease stresses systems", "PROBLEM", 0, 44], ["infectious", "OBSERVATION", 9, 19], ["variety", "OBSERVATION_MODIFIER", 54, 61]]], ["Although CL psychiatry has largely focused on individual biological and psychological systems and on interpersonal interactions within medical care systems, the context of the pandemic/epidemic demands that we extend our skills to broader social systems as well.", [["CL", "MULTI-TISSUE_STRUCTURE", 9, 11], ["the pandemic/epidemic demands", "PROBLEM", 172, 201]]], ["For instance, can psychiatrists assist in devising mass interventions aimed at encouraging the public to participate in prevention strategies like social distancing and voluntary quarantine?Supporting the system ::: Roles for the CL psychiatrist in the COVID-19 pandemicIn Wuhan, mental health providers participated in creating and providing publicly available informational materials about COVID-19.", [["mass interventions", "TREATMENT", 51, 69], ["prevention strategies", "TREATMENT", 120, 141], ["COVID", "TEST", 392, 397]]], ["These materials included education on mental health in the setting of COVID disseminated to the public in conjunction with materials on prevention and control [21].", [["COVID disseminated", "PROBLEM", 70, 88], ["disseminated", "OBSERVATION", 76, 88]]], ["Given the expertise of CL psychiatrists in issues related to health anxiety and health communication, there is a clear role for our expertise in crafting such society-wide interventions.Supporting the system ::: Roles for the CL psychiatrist in the COVID-19 pandemicOn another note, medicolegal standards may change during epidemics.", [["anxiety", "DISEASE", 68, 75], ["CL", "MULTI-TISSUE_STRUCTURE", 23, 25], ["health anxiety", "PROBLEM", 61, 75], ["wide interventions", "TREATMENT", 167, 185]]], ["Such changes may have unique effects on patients with comorbid mental illness [22].", [["comorbid mental illness", "DISEASE", 54, 77], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["comorbid mental illness", "PROBLEM", 54, 77]]], ["CL psychiatrists should contribute to analysis of complex ethical challenges, especially as they pertain to psychiatric issues, for example quarantining unwilling patients whose judgment is impaired by mental illness.Exposure ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingMental health services\u2014particularly CL services in medical hospitals\u2014may consist of only a few clinicians.", [["psychiatric", "DISEASE", 108, 119], ["impaired by mental illness", "DISEASE", 190, 216], ["psychiatric", "DISEASE", 275, 286], ["CL", "MULTI-TISSUE_STRUCTURE", 0, 2], ["patients", "ORGANISM", 163, 171], ["CL", "MULTI-TISSUE_STRUCTURE", 351, 353], ["patients", "SPECIES", 163, 171], ["mental illness", "PROBLEM", 202, 216]]], ["In our institution, we are utilizing a multi-level exposure-prevention and mitigation strategy based on existing evidence to both limit individual exposure and protect the service.Exposure ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingOn the individual level, we recommend ensuring that all staff have access to and training regarding appropriate use of personal protective equipment (PPE) [23].", [["psychiatric", "DISEASE", 238, 249], ["a multi-level exposure-prevention", "TREATMENT", 37, 70], ["mitigation strategy", "TREATMENT", 75, 94], ["personal protective equipment", "TREATMENT", 397, 426]]], ["We also suggest utilization of new technologies and models of care to limit individual exposure when consulting on potentially infectious patients.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["new technologies", "TREATMENT", 31, 47]]], ["Our service has found the use of video consultations using smartphones, tablets, or computers particularly helpful.", [["smartphones", "TREATMENT", 59, 70], ["tablets", "TREATMENT", 72, 79]]], ["Many patients have such devices.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["such devices", "TREATMENT", 19, 31]]], ["Given the deficit of PPE nationally, utilizing video consultation is also of benefit to the system and this is reflected in changes in billing and compliance rules to facilitate such consultative models during the epidemic.", [["video consultation", "TEST", 47, 65]]], ["Frontline staff including nurses and primary team physicians can help patients \u201cset up\u201d video conferences with psychiatrists.Exposure ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingIn areas where connectivity may preclude video consultation, other novel techniques are being developed.", [["psychiatric", "DISEASE", 183, 194], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["video consultation", "TEST", 264, 282], ["other novel techniques", "TREATMENT", 284, 306]]], ["In Wuhan, mental health providers utilized a written modality of psychiatric consultation they titled \u201cstructured letter therapy\u201d which entailed the exchange of structured written communication between therapists and patients under treatment for COVID-19.", [["psychiatric", "DISEASE", 65, 76], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["COVID", "TEST", 246, 251]]], ["Although outcomes data for this intervention is not yet available, the authors suggest this was a means to serve a greater number of patients while mitigating exposure of the limited mental health workforce [24].Exposure ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingOn the service-level, we recommend limiting all in-person service meetings and shifting to remote video-meeting.", [["psychiatric", "DISEASE", 270, 281], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["this intervention", "TREATMENT", 27, 44]]], ["Staff on our service are encouraged to bring clothing changes or wear in-hospital scrubs to prevent contamination.", [["contamination", "PROBLEM", 100, 113]]], ["Finally, consider limiting consultation on infectious COVID-19 patients to a small number of low-risk volunteer consultants to prevent unnecessary exposure of the entire service [23].Morale ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingPsychiatrists and mental health clinicians are not immune to demoralization, burnout, and fear associated with being at the frontlines of a dangerous epidemic.", [["psychiatric", "DISEASE", 239, 250], ["demoralization", "DISEASE", 340, 354], ["burnout", "DISEASE", 356, 363], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["burnout", "PROBLEM", 356, 363]]], ["We recommend daily update communications, including open discussion around concerns of infecting family members, protocols for arrival home and surface decontamination, and so forth.", [["surface", "ANATOMY", 144, 151], ["surface decontamination", "TREATMENT", 144, 167]]], ["We also suggest system-wide monitoring of the supply of PPE, given potential shortages [3].", [["PPE", "PROBLEM", 56, 59]]], ["Along with exposure prevention and staggered staffing, services should utilize creative staffing arrangements to accommodate staffing challenges around child and eldercare and to ensure staff have adequate rest.", [["exposure prevention", "TREATMENT", 11, 30]]], ["Services should extend extra care to check in with trainees on the service to ensure they feel safe and supported in their roles.Value added ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingEnsuring that our medical collaborators understand the roles of psychiatry in the context of epidemic response is a particular challenge given our own field only beginning to understand and define this role.", [["psychiatric", "DISEASE", 190, 201]]], ["Our approach to combating this lack of understanding is twofold: first, to work assiduously as a service to respond to the needs of our patients, institution, and community.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144]]], ["Sharing our contributions with our institutions and our discipline allows us to identify to ourselves and others how we can best be of use, and also to improve best practices across our entire community.Value added ::: Challenges to providing consultation-liaison psychiatric care in the COVID-19 settingCOVID-19 and other emerging infectious disease pandemic/epidemics represent a sobering reality of our increasingly connected world.", [["psychiatric", "DISEASE", 264, 275], ["infectious disease pandemic", "DISEASE", 332, 359], ["epidemics", "PROBLEM", 360, 369], ["infectious", "OBSERVATION", 332, 342]]], ["Epidemic CL psychiatry will demand creative new models of advocacy and care delivery, more engagement by CL psychiatry with staff support and social education interventions, and management of heretofore unanticipated risks.", [["CL", "MULTI-TISSUE_STRUCTURE", 9, 11], ["CL", "MULTI-TISSUE_STRUCTURE", 105, 107], ["care delivery", "TREATMENT", 71, 84], ["staff support", "TREATMENT", 124, 137], ["social education interventions", "TREATMENT", 142, 172]]], ["The roles we identify for psychiatrists are aspirational.", [["aspirational", "PROBLEM", 44, 56]]], ["No service, no matter how well staffed, can fill each of these roles.", [["no", "UNCERTAINTY", 12, 14]]], ["These challenges are also opportunities: opportunities for our field to grow and evolve in its roles, opportunities to push scholarship in mental health in new directions, and, most importantly, opportunities to support our patients and communities in a moment of great need.Funding and supportNone.DisclaimersNone.Declaration of competing interestNone.", [["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["supportNone", "TREATMENT", 287, 298]]]], "PMC7380894": [["In Brazil, the first COVID-19 case was confirmed on February 26, 2020, and by May 26, 2020, the number of confirmed cases was of 391,222, with 24,512 confirmed deaths [1].", [["deaths", "DISEASE", 160, 166]]], ["CT and [18F]FDG PET/CT findings in COVID-19 have been described in several reports [2, 3], but to our knowledge findings in [68Ga]-labeled radiopharmaceuticals PET/CT remain to be described.", [["[18F]FDG", "CHEMICAL", 7, 15], ["[18F]FDG", "SIMPLE_CHEMICAL", 7, 15], ["[68Ga]-", "SIMPLE_CHEMICAL", 124, 131], ["CT", "TEST", 0, 2], ["FDG PET/CT findings", "TEST", 12, 31], ["COVID", "TEST", 35, 40], ["labeled radiopharmaceuticals PET/CT", "TEST", 131, 166]]]], "PMC7256611": [["The goal of this paper is to revisit the 2016 American Association of Colleges of Nursing (AACN) academic nursing position statement (American Association of Colleges of Nursing, 2016) associated with health care reform, and reimagine it as a means to maximize nursing's contribution to global health crises like COVID-19.", [["global health crises", "PROBLEM", 287, 307], ["COVID", "TEST", 313, 318]]]], "PMC7505936": [["The universality and severity of mental diseases ::: BackgroundExcluding acute lung, heart, kidney and other organic damage, psychological damage may have a wide and long-term impact.", [["lung", "ANATOMY", 79, 83], ["heart", "ANATOMY", 85, 90], ["kidney", "ANATOMY", 92, 98], ["acute lung, heart, kidney and other organic damage", "DISEASE", 73, 123], ["psychological damage", "DISEASE", 125, 145], ["lung", "ORGAN", 79, 83], ["heart", "ORGAN", 85, 90], ["kidney", "ORGAN", 92, 98], ["mental diseases", "PROBLEM", 33, 48], ["acute lung, heart, kidney", "PROBLEM", 73, 98], ["other organic damage", "PROBLEM", 103, 123], ["psychological damage", "PROBLEM", 125, 145], ["a wide and long-term impact", "PROBLEM", 155, 182], ["mental diseases", "OBSERVATION", 33, 48], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["lung", "ANATOMY", 79, 83], ["heart", "ANATOMY", 85, 90], ["kidney", "ANATOMY", 92, 98], ["organic damage", "OBSERVATION", 109, 123], ["wide", "OBSERVATION_MODIFIER", 157, 161], ["long-term impact", "OBSERVATION_MODIFIER", 166, 182]]], ["The outbreak of SARS in 2003 can be regarded as a mental health disaster.", [["SARS", "DISEASE", 16, 20]]], ["PTSD is the most common chronic psychosis, followed by depression.", [["PTSD", "DISEASE", 0, 4], ["chronic psychosis", "DISEASE", 24, 41], ["depression", "DISEASE", 55, 65], ["PTSD", "PROBLEM", 0, 4], ["chronic psychosis", "PROBLEM", 24, 41], ["depression", "PROBLEM", 55, 65], ["most common", "OBSERVATION_MODIFIER", 12, 23], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["psychosis", "OBSERVATION", 32, 41]]], ["The problem of mental illness after the epidemic is extremely serious, and its influence covers all fields and is closely related to everyone.", [["mental illness", "PROBLEM", 15, 29], ["serious", "OBSERVATION_MODIFIER", 62, 69]]], ["In one follow-up study of 195 adult SARS patients, 10 to 18% reported PTSD 1 month after discharge, and the severity of symptoms was related to higher perceived life threat and lower emotional support [7].", [["SARS", "DISEASE", 36, 40], ["PTSD", "DISEASE", 70, 74], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["symptoms", "PROBLEM", 120, 128]]], ["Another study of 180 SARS survivors (average age 36.9 years) also pointed out that the psychological distress in them after 1 month\u2019s recovery was real and significant, and negative assessment may play a key role in the development of psychological distress in these survivors.", [["SARS", "DISEASE", 21, 25], ["psychological distress", "DISEASE", 235, 257], ["Another study", "TEST", 0, 13], ["the psychological distress", "PROBLEM", 83, 109], ["psychological distress", "PROBLEM", 235, 257]]], ["For instance, the negative appraisal of acute phase with significant influence was \u2018passing the SARS virus on to the family\u2019, whereas the convalescence after recovery was changed to \u2018drug side-effects\u2019 and \u2018permanent damage to health\u2019 [8].", [["SARS", "DISEASE", 96, 100], ["SARS virus", "SPECIES", 96, 106], ["acute phase", "PROBLEM", 40, 51], ["significant influence", "PROBLEM", 57, 78], ["the SARS virus", "PROBLEM", 92, 106], ["acute", "OBSERVATION_MODIFIER", 40, 45]]], ["For SARS patients, compared with a control group, the study showed that the stress level was higher during the outbreak and no sign of decline after 1 year.The universality and severity of mental diseases ::: BackgroundSARS survivors also showed worrisome depression, anxiety and post-traumatic symptoms, with an alarming proportion (64%) of those who had reached the diagnostic criteria for psychosis [9].", [["SARS", "DISEASE", 4, 8], ["depression", "DISEASE", 256, 266], ["anxiety", "DISEASE", 268, 275], ["post-traumatic symptoms", "DISEASE", 280, 303], ["psychosis", "DISEASE", 392, 401], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["SARS", "PROBLEM", 4, 8], ["the study", "TEST", 50, 59], ["the stress level", "TEST", 72, 88], ["mental diseases", "PROBLEM", 189, 204], ["worrisome depression", "PROBLEM", 246, 266], ["anxiety", "PROBLEM", 268, 275], ["post-traumatic symptoms", "PROBLEM", 280, 303], ["psychosis", "PROBLEM", 392, 401], ["no sign of", "UNCERTAINTY", 124, 134], ["mental diseases", "OBSERVATION", 189, 204], ["worrisome", "OBSERVATION_MODIFIER", 246, 255], ["depression", "OBSERVATION", 256, 266]]], ["More studies have shown that in the 4 years of SARS treatment, PTSD occurred in a high proportion (44.1%) of subjects who recovered from SARS, with persistent psychological distress and social function weakening [10], and such a huge psychological trauma was also observed in Middle East Respiratory Syndrome (MERS) [11].", [["SARS", "DISEASE", 47, 51], ["PTSD", "DISEASE", 63, 67], ["SARS", "DISEASE", 137, 141], ["trauma", "DISEASE", 248, 254], ["Middle East Respiratory Syndrome", "DISEASE", 276, 308], ["MERS", "DISEASE", 310, 314], ["More studies", "TEST", 0, 12], ["SARS treatment", "TREATMENT", 47, 61], ["PTSD", "PROBLEM", 63, 67], ["SARS", "PROBLEM", 137, 141], ["persistent psychological distress", "PROBLEM", 148, 181], ["social function weakening", "PROBLEM", 186, 211], ["a huge psychological trauma", "PROBLEM", 227, 254], ["Respiratory Syndrome", "PROBLEM", 288, 308], ["Middle", "ANATOMY_MODIFIER", 276, 282], ["Respiratory Syndrome", "OBSERVATION", 288, 308]]], ["However, mental and psychological stress and post-traumatic stress disorder not only cause great persistent damage to patients themselves, but also post serious threats to their contacts.", [["post-traumatic stress disorder", "DISEASE", 45, 75], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["mental and psychological stress", "PROBLEM", 9, 40], ["post-traumatic stress disorder", "PROBLEM", 45, 75], ["great persistent damage to patients themselves", "PROBLEM", 91, 137], ["persistent", "OBSERVATION_MODIFIER", 97, 107], ["damage", "OBSERVATION", 108, 114]]], ["Due to the pressure of contagion, people tend to vent their emotions to innocent people, and those who feel exposed to danger may have a strong tendency to insult others and even resort to violence against them [12], like what happened in Ukraine.The universality and severity of mental diseases ::: BackgroundNotably, the mental health of survivors in terms of stress, anxiety, depression and post-traumatic symptoms did not improve over time, but gradually deteriorated [13].", [["violence", "DISEASE", 189, 197], ["anxiety", "DISEASE", 370, 377], ["depression", "DISEASE", 379, 389], ["post-traumatic symptoms", "DISEASE", 394, 417], ["people", "ORGANISM", 34, 40], ["people", "ORGANISM", 81, 87], ["people", "SPECIES", 34, 40], ["people", "SPECIES", 81, 87], ["mental diseases", "PROBLEM", 280, 295], ["stress", "PROBLEM", 362, 368], ["anxiety", "PROBLEM", 370, 377], ["depression", "PROBLEM", 379, 389], ["post-traumatic symptoms", "PROBLEM", 394, 417], ["mental diseases", "OBSERVATION", 280, 295]]], ["The study found that most of the first symptoms of depression occurred in the late stage of treatment and 3 months after discharge, while the existence of some protective factors such as feeling lucky, increased civic awareness and a sense of solidarity, played a role in alleviating depression, but as the epidemic passed, the buffering effect gradually weakened, and then the depression continued to grow [8].", [["depression", "DISEASE", 51, 61], ["depression", "DISEASE", 284, 294], ["depression", "DISEASE", 378, 388], ["The study", "TEST", 0, 9], ["the first symptoms", "PROBLEM", 29, 47], ["depression", "PROBLEM", 51, 61], ["alleviating depression", "PROBLEM", 272, 294], ["the depression", "PROBLEM", 374, 388], ["depression", "OBSERVATION", 51, 61], ["late stage", "OBSERVATION_MODIFIER", 78, 88]]], ["Another report also confirmed this: when life is no longer under imminent threat, other concerns gradually emerge, such as the fear in isolation ward, complications of SARS and their treatment (such as avascular necrosis of the femoral head and osteoporosis), discrimination, unemployment, economic pressure, or the threat of other subsequent outbreaks of infectious diseases that may or have occurred [14].The pathogenesis of mental diseases after highly infectious diseases ::: BackgroundIt is reported that neuroendocrine, neural structure and neuroimmune disorders play an important role in depression and PTSD.", [["avascular", "ANATOMY", 202, 211], ["femoral head", "ANATOMY", 228, 240], ["neuroendocrine", "ANATOMY", 510, 524], ["neural structure", "ANATOMY", 526, 542], ["SARS", "DISEASE", 168, 172], ["avascular necrosis of the femoral head", "DISEASE", 202, 240], ["osteoporosis", "DISEASE", 245, 257], ["infectious diseases", "DISEASE", 356, 375], ["infectious diseases", "DISEASE", 456, 475], ["neuroimmune disorders", "DISEASE", 547, 568], ["depression", "DISEASE", 595, 605], ["PTSD", "DISEASE", 610, 614], ["femoral head", "MULTI-TISSUE_STRUCTURE", 228, 240], ["neuroendocrine", "CELL", 510, 524], ["SARS", "PROBLEM", 168, 172], ["their treatment", "TREATMENT", 177, 192], ["avascular necrosis of the femoral head", "PROBLEM", 202, 240], ["osteoporosis", "PROBLEM", 245, 257], ["economic pressure", "TEST", 290, 307], ["infectious diseases", "PROBLEM", 356, 375], ["mental diseases", "PROBLEM", 427, 442], ["neuroendocrine, neural structure and neuroimmune disorders", "PROBLEM", 510, 568], ["depression", "PROBLEM", 595, 605], ["PTSD", "PROBLEM", 610, 614], ["no longer", "UNCERTAINTY", 49, 58], ["avascular", "OBSERVATION_MODIFIER", 202, 211], ["necrosis", "OBSERVATION", 212, 220], ["femoral head", "ANATOMY", 228, 240], ["osteoporosis", "OBSERVATION", 245, 257], ["infectious", "OBSERVATION", 356, 366], ["mental diseases", "OBSERVATION", 427, 442], ["infectious", "OBSERVATION", 456, 466], ["neural structure", "OBSERVATION", 526, 542], ["neuroimmune disorders", "OBSERVATION", 547, 568]]], ["On the one hand, coronavirus can guide the immune damage mechanism in the body and induce a large number of inflammatory reactions.", [["body", "ANATOMY", 74, 78], ["coronavirus", "ORGANISM", 17, 28], ["body", "ORGANISM_SUBDIVISION", 74, 78], ["coronavirus", "PROBLEM", 17, 28], ["the immune damage mechanism in the body", "PROBLEM", 39, 78], ["inflammatory reactions", "PROBLEM", 108, 130], ["coronavirus", "OBSERVATION", 17, 28], ["body", "ANATOMY", 74, 78], ["large", "OBSERVATION_MODIFIER", 92, 97], ["number", "OBSERVATION_MODIFIER", 98, 104], ["inflammatory", "OBSERVATION_MODIFIER", 108, 120]]], ["In the blood and Cerebrospinal fluid (CSF) of patients with coronavirus pneumonia, Interleukin-6(IL-6), C-reactive protein (CRP), Interleukin-1(IL-1), Tumor Necrosis Factor (TNF) and other proinflammatory factors are all increased to varying degrees [15], among with high levels of IL-6 are strongly related to progressive neurological dysfunction, neurodegeneration and cognitive impairment [16].", [["blood", "ANATOMY", 7, 12], ["Cerebrospinal fluid", "ANATOMY", 17, 36], ["neurological", "ANATOMY", 323, 335], ["coronavirus pneumonia", "DISEASE", 60, 81], ["neurological dysfunction", "DISEASE", 323, 347], ["neurodegeneration", "DISEASE", 349, 366], ["cognitive impairment", "DISEASE", 371, 391], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 17, 36], ["CSF", "ORGANISM_SUBSTANCE", 38, 41], ["patients", "ORGANISM", 46, 54], ["coronavirus", "ORGANISM", 60, 71], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 83, 96], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 104, 122], ["CRP", "GENE_OR_GENE_PRODUCT", 124, 127], ["Interleukin-1", "GENE_OR_GENE_PRODUCT", 130, 143], ["IL-1", "GENE_OR_GENE_PRODUCT", 144, 148], ["Tumor Necrosis Factor", "GENE_OR_GENE_PRODUCT", 151, 172], ["TNF", "GENE_OR_GENE_PRODUCT", 174, 177], ["IL-6", "GENE_OR_GENE_PRODUCT", 282, 286], ["Interleukin-6(IL-6", "PROTEIN", 83, 101], ["C-reactive protein", "PROTEIN", 104, 122], ["CRP", "PROTEIN", 124, 127], ["Interleukin-1(IL-1", "PROTEIN", 130, 148], ["Tumor Necrosis Factor", "PROTEIN", 151, 172], ["TNF", "PROTEIN", 174, 177], ["proinflammatory factors", "PROTEIN", 189, 212], ["IL-6", "PROTEIN", 282, 286], ["patients", "SPECIES", 46, 54], ["coronavirus", "SPECIES", 60, 71], ["the blood", "TEST", 3, 12], ["Cerebrospinal fluid (CSF", "TEST", 17, 41], ["coronavirus pneumonia", "PROBLEM", 60, 81], ["Interleukin", "TEST", 83, 94], ["IL", "TEST", 97, 99], ["C-reactive protein", "TEST", 104, 122], ["CRP", "TEST", 124, 127], ["Interleukin", "TEST", 130, 141], ["IL", "TEST", 144, 146], ["Tumor Necrosis Factor (TNF)", "PROBLEM", 151, 178], ["other proinflammatory factors", "PROBLEM", 183, 212], ["progressive neurological dysfunction", "PROBLEM", 311, 347], ["neurodegeneration", "PROBLEM", 349, 366], ["cognitive impairment", "PROBLEM", 371, 391], ["blood", "ANATOMY", 7, 12], ["Cerebrospinal", "ANATOMY", 17, 30], ["fluid", "OBSERVATION", 31, 36], ["coronavirus", "OBSERVATION_MODIFIER", 60, 71], ["pneumonia", "OBSERVATION", 72, 81], ["Tumor", "OBSERVATION_MODIFIER", 151, 156], ["Necrosis", "OBSERVATION", 157, 165], ["progressive", "OBSERVATION_MODIFIER", 311, 322], ["neurological dysfunction", "OBSERVATION", 323, 347]]], ["This probably the mechanism how the virus affects the patient\u2019s mental health molecularly.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61]]], ["And many evidences show that the inflammatory reaction in the lung, heart and nervous system will last for a long time in the prognosis of SARS [17], and lead to a variety of chronic inflammatory diseases such as pulmonary fibrosis, viral myocarditis, multiple sclerosis [18], while the chronic inflammation, especially the inflammatory complications of the nervous system related to the changes of brain structure and function, which is considered to be one of the pathogenesis of depression [19, 20].", [["lung", "ANATOMY", 62, 66], ["heart", "ANATOMY", 68, 73], ["nervous system", "ANATOMY", 78, 92], ["pulmonary", "ANATOMY", 213, 222], ["nervous system", "ANATOMY", 358, 372], ["brain", "ANATOMY", 399, 404], ["SARS", "DISEASE", 139, 143], ["pulmonary fibrosis", "DISEASE", 213, 231], ["viral myocarditis", "DISEASE", 233, 250], ["multiple sclerosis", "DISEASE", 252, 270], ["inflammation", "DISEASE", 295, 307], ["depression", "DISEASE", 482, 492], ["lung", "ORGAN", 62, 66], ["heart", "ORGAN", 68, 73], ["nervous system", "ANATOMICAL_SYSTEM", 78, 92], ["pulmonary", "ORGAN", 213, 222], ["nervous system", "ANATOMICAL_SYSTEM", 358, 372], ["brain", "ORGAN", 399, 404], ["the inflammatory reaction in the lung, heart and nervous system", "PROBLEM", 29, 92], ["SARS", "PROBLEM", 139, 143], ["chronic inflammatory diseases", "PROBLEM", 175, 204], ["pulmonary fibrosis", "PROBLEM", 213, 231], ["viral myocarditis", "PROBLEM", 233, 250], ["multiple sclerosis", "PROBLEM", 252, 270], ["the chronic inflammation", "PROBLEM", 283, 307], ["the inflammatory complications of the nervous system", "PROBLEM", 320, 372], ["depression", "PROBLEM", 482, 492], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["reaction", "OBSERVATION", 46, 54], ["lung", "ANATOMY", 62, 66], ["heart", "ANATOMY", 68, 73], ["nervous system", "ANATOMY", 78, 92], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["inflammatory", "OBSERVATION", 183, 195], ["pulmonary", "ANATOMY", 213, 222], ["fibrosis", "OBSERVATION", 223, 231], ["viral", "OBSERVATION_MODIFIER", 233, 238], ["myocarditis", "OBSERVATION", 239, 250], ["multiple", "OBSERVATION_MODIFIER", 252, 260], ["sclerosis", "OBSERVATION", 261, 270], ["chronic", "OBSERVATION_MODIFIER", 287, 294], ["inflammation", "OBSERVATION", 295, 307], ["inflammatory", "OBSERVATION_MODIFIER", 324, 336], ["complications", "OBSERVATION", 337, 350], ["nervous system", "ANATOMY", 358, 372], ["brain", "ANATOMY", 399, 404]]], ["On the other hand, the inflammatory reaction of the nervous system will cause the metabolic changes of the basal ganglia and affect the information processing through the cingulate cortex.", [["nervous system", "ANATOMY", 52, 66], ["basal ganglia", "ANATOMY", 107, 120], ["cingulate cortex", "ANATOMY", 171, 187], ["nervous system", "ANATOMICAL_SYSTEM", 52, 66], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 107, 120], ["cingulate cortex", "MULTI-TISSUE_STRUCTURE", 171, 187], ["the inflammatory reaction of the nervous system", "PROBLEM", 19, 66], ["the metabolic changes of the basal ganglia", "PROBLEM", 78, 120], ["inflammatory", "OBSERVATION", 23, 35], ["nervous", "ANATOMY", 52, 59], ["metabolic changes", "OBSERVATION", 82, 99], ["basal ganglia", "ANATOMY", 107, 120], ["cingulate cortex", "ANATOMY", 171, 187]]], ["Changes in the cingulate cortex may indicate increased sensitivity to conflict and negative life events [21], which further complements the possible pathogenesis of depression in patients with COVID-19 .The pathogenesis of mental diseases after highly infectious diseases ::: BackgroundSecondly, in PSTD, the increase of corticotropin releasing factor (CRF) induced by traumatic stress may play an important role in the process of enhancing activated macrophage releasing facto [22], and these macrophages are widely distributed in the peripheral nervous system and brain, thus causing stress response to the decrease of stress threshold.The pathogenesis of mental diseases after highly infectious diseases ::: BackgroundThe long-term prognosis of COVID-19 patients with mental disorders after rehabilitation is similar to that of SARS and other major epidemics [23], and its severity and persistence are immeasurable.", [["cingulate cortex", "ANATOMY", 15, 31], ["macrophage", "ANATOMY", 451, 461], ["macrophages", "ANATOMY", 494, 505], ["peripheral nervous system", "ANATOMY", 536, 561], ["brain", "ANATOMY", 566, 571], ["depression", "DISEASE", 165, 175], ["infectious diseases", "DISEASE", 252, 271], ["CRF", "DISEASE", 353, 356], ["infectious diseases", "DISEASE", 687, 706], ["COVID", "DISEASE", 748, 753], ["mental disorders", "DISEASE", 771, 787], ["SARS", "DISEASE", 831, 835], ["cingulate cortex", "MULTI-TISSUE_STRUCTURE", 15, 31], ["patients", "ORGANISM", 179, 187], ["corticotropin releasing factor", "GENE_OR_GENE_PRODUCT", 321, 351], ["CRF", "GENE_OR_GENE_PRODUCT", 353, 356], ["macrophage", "CELL", 451, 461], ["macrophages", "CELL", 494, 505], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 536, 561], ["brain", "ORGAN", 566, 571], ["patients", "ORGANISM", 757, 765], ["corticotropin releasing factor", "PROTEIN", 321, 351], ["CRF", "PROTEIN", 353, 356], ["activated macrophage", "CELL_TYPE", 441, 461], ["macrophages", "CELL_TYPE", 494, 505], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 757, 765], ["Changes in the cingulate cortex", "PROBLEM", 0, 31], ["increased sensitivity", "PROBLEM", 45, 66], ["depression", "PROBLEM", 165, 175], ["COVID", "TEST", 193, 198], ["mental diseases", "PROBLEM", 223, 238], ["corticotropin releasing factor (CRF)", "PROBLEM", 321, 357], ["traumatic stress", "PROBLEM", 369, 385], ["stress response", "PROBLEM", 586, 601], ["the decrease of stress threshold", "PROBLEM", 605, 637], ["mental diseases", "PROBLEM", 658, 673], ["COVID", "TEST", 748, 753], ["mental disorders", "PROBLEM", 771, 787], ["rehabilitation", "TREATMENT", 794, 808], ["SARS", "PROBLEM", 831, 835], ["cingulate", "ANATOMY_MODIFIER", 15, 24], ["cortex", "ANATOMY_MODIFIER", 25, 31], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["possible", "UNCERTAINTY", 140, 148], ["mental diseases", "OBSERVATION", 223, 238], ["infectious", "OBSERVATION", 252, 262], ["increase", "OBSERVATION_MODIFIER", 309, 317], ["macrophages", "OBSERVATION", 494, 505], ["widely", "OBSERVATION_MODIFIER", 510, 516], ["peripheral", "ANATOMY_MODIFIER", 536, 546], ["nervous system", "ANATOMY", 547, 561], ["brain", "ANATOMY", 566, 571], ["stress response", "OBSERVATION", 586, 601], ["decrease", "OBSERVATION_MODIFIER", 609, 617], ["mental diseases", "OBSERVATION", 658, 673], ["infectious", "OBSERVATION", 687, 697], ["long-term", "OBSERVATION_MODIFIER", 725, 734]]], ["The study points out that with the delay of time and the deepening of symptoms, the proinflammatory cytokines in patients with depression, fatigue and severe insomnia will further increase, which will aggravate the complications of other organ systems [24, 25].", [["organ", "ANATOMY", 238, 243], ["depression", "DISEASE", 127, 137], ["fatigue", "DISEASE", 139, 146], ["insomnia", "DISEASE", 158, 166], ["patients", "ORGANISM", 113, 121], ["organ", "ORGAN", 238, 243], ["proinflammatory cytokines", "PROTEIN", 84, 109], ["patients", "SPECIES", 113, 121], ["The study", "TEST", 0, 9], ["symptoms", "PROBLEM", 70, 78], ["the proinflammatory cytokines", "PROBLEM", 80, 109], ["depression", "PROBLEM", 127, 137], ["fatigue", "PROBLEM", 139, 146], ["severe insomnia", "PROBLEM", 151, 166], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["insomnia", "OBSERVATION", 158, 166]]], ["Long term depression is an important cause of cognitive decline and neurodegenerative change, and the activation of macrophages in the blood and microglia in the brain caused by chronic inflammation will further aggravate neurodegenerative change, which is closely related to the transformation from depression to dementia [19].", [["macrophages", "ANATOMY", 116, 127], ["blood", "ANATOMY", 135, 140], ["microglia", "ANATOMY", 145, 154], ["brain", "ANATOMY", 162, 167], ["depression", "DISEASE", 10, 20], ["cognitive decline", "DISEASE", 46, 63], ["inflammation", "DISEASE", 186, 198], ["depression", "DISEASE", 300, 310], ["dementia", "DISEASE", 314, 322], ["macrophages", "CELL", 116, 127], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["microglia", "CELL", 145, 154], ["brain", "ORGAN", 162, 167], ["macrophages", "CELL_TYPE", 116, 127], ["microglia", "CELL_TYPE", 145, 154], ["Long term depression", "PROBLEM", 0, 20], ["cognitive decline", "PROBLEM", 46, 63], ["neurodegenerative change", "PROBLEM", 68, 92], ["macrophages in the blood and microglia in the brain", "PROBLEM", 116, 167], ["chronic inflammation", "PROBLEM", 178, 198], ["further aggravate neurodegenerative change", "PROBLEM", 204, 246], ["depression", "PROBLEM", 300, 310], ["dementia", "PROBLEM", 314, 322], ["depression", "OBSERVATION", 10, 20], ["important cause of", "UNCERTAINTY", 27, 45], ["cognitive decline", "OBSERVATION", 46, 63], ["neurodegenerative", "OBSERVATION_MODIFIER", 68, 85], ["change", "OBSERVATION", 86, 92], ["macrophages", "OBSERVATION", 116, 127], ["blood", "ANATOMY", 135, 140], ["microglia", "ANATOMY", 145, 154], ["brain", "ANATOMY", 162, 167], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["inflammation", "OBSERVATION", 186, 198], ["aggravate", "OBSERVATION_MODIFIER", 212, 221], ["neurodegenerative", "OBSERVATION_MODIFIER", 222, 239], ["change", "OBSERVATION", 240, 246]]], ["Therefore, extensive psychological treatment and counseling services need to be paid attention to and to strictly control the progress of mental and psychological diseases.High risk factors of mental disorders caused by COVID-19 ::: BackgroundIn previous retrospective studies, the occurrence of psychosocial diseases is often strongly associated with specific population or special environmental factors.", [["mental disorders", "DISEASE", 193, 209], ["psychosocial diseases", "DISEASE", 296, 317], ["COVID-19", "CHEMICAL", 220, 228], ["extensive psychological treatment", "TREATMENT", 11, 44], ["counseling services", "TREATMENT", 49, 68], ["mental and psychological diseases", "PROBLEM", 138, 171], ["mental disorders", "PROBLEM", 193, 209], ["previous retrospective studies", "TEST", 246, 276], ["psychosocial diseases", "PROBLEM", 296, 317], ["psychosocial diseases", "OBSERVATION", 296, 317]]], ["For example, although the stress level of medical staff among SARS survivors during the outbreak was similar to that of non-medical staff, a year later, the pressure level of medical staff was significantly higher, with higher levels of depression, anxiety, post-traumatic symptoms and scores.", [["SARS", "DISEASE", 62, 66], ["depression", "DISEASE", 237, 247], ["anxiety", "DISEASE", 249, 256], ["depression", "PROBLEM", 237, 247], ["anxiety", "PROBLEM", 249, 256], ["post-traumatic symptoms", "PROBLEM", 258, 281]]], ["After controlling factors such as age, gender and education, health care workers are six times more likely to score above the General Health Questionnaire-12 (GHQ-12) threshold due to the dual pressure of being patients and medical staff [26], so the situation of SARS survivors among medical staff is particularly worrying and they need more attention [26].", [["SARS", "DISEASE", 264, 268], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219]]], ["17.3% of the medical staff without the disease had similar mental symptoms [27], including chronic fatigue, pain, weakness, depression and sleep disorders [28].", [["chronic fatigue", "DISEASE", 91, 106], ["pain", "DISEASE", 108, 112], ["weakness", "DISEASE", 114, 122], ["depression", "DISEASE", 124, 134], ["sleep disorders", "DISEASE", 139, 154], ["the disease", "PROBLEM", 35, 46], ["similar mental symptoms", "PROBLEM", 51, 74], ["chronic fatigue", "PROBLEM", 91, 106], ["pain", "PROBLEM", 108, 112], ["weakness", "PROBLEM", 114, 122], ["depression", "PROBLEM", 124, 134], ["sleep disorders", "PROBLEM", 139, 154], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["fatigue", "OBSERVATION", 99, 106], ["weakness", "OBSERVATION", 114, 122]]], ["Over the long term, of the 90 subjects recruited, a quarter had post-traumatic stress disorder (PTSD) 30 months after SARS, while 15.6% had depression [13].", [["post-traumatic stress disorder", "DISEASE", 64, 94], ["PTSD", "DISEASE", 96, 100], ["SARS", "DISEASE", 118, 122], ["depression", "DISEASE", 140, 150], ["post-traumatic stress disorder", "PROBLEM", 64, 94], ["SARS", "PROBLEM", 118, 122], ["depression", "PROBLEM", 140, 150], ["long term", "OBSERVATION_MODIFIER", 9, 18]]], ["What\u2019s more, different occupations have different effects on mental health, doctors have more physical symptoms compared to nurses [29].", [["more physical symptoms", "PROBLEM", 89, 111]]], ["Our results, therefore, highlight the need to enhance the preparedness and capacity of healthcare professionals to detect and manage the psychological consequences of future comparable outbreaks of infectious diseases.High risk factors of mental disorders caused by COVID-19 ::: BackgroundThe infection of virus is not only the battle of patients and medical staff, but also the battle of the whole country and people, as it is closely related to everyone and no one can stay out of the business.", [["infectious diseases", "DISEASE", 198, 217], ["mental disorders", "DISEASE", 239, 255], ["infection", "DISEASE", 293, 302], ["COVID-19", "CHEMICAL", 266, 274], ["patients", "ORGANISM", 338, 346], ["people", "ORGANISM", 411, 417], ["patients", "SPECIES", 338, 346], ["people", "SPECIES", 411, 417], ["infectious diseases", "PROBLEM", 198, 217], ["mental disorders", "PROBLEM", 239, 255], ["The infection of virus", "PROBLEM", 289, 311], ["infectious", "OBSERVATION", 198, 208], ["infection", "OBSERVATION", 293, 302], ["virus", "OBSERVATION", 306, 311]]], ["Studies have showed that the residents in the areas with high prevalence of SARS, regardless of age, continued to develop more serious post-traumatic interference than those in the areas with low prevalence of SARS.", [["SARS", "DISEASE", 76, 80], ["SARS", "DISEASE", 210, 214], ["Studies", "TEST", 0, 7], ["SARS", "PROBLEM", 76, 80], ["more serious post-traumatic interference", "PROBLEM", 122, 162], ["SARS", "PROBLEM", 210, 214], ["high prevalence", "OBSERVATION_MODIFIER", 57, 72], ["serious", "OBSERVATION_MODIFIER", 127, 134], ["post-traumatic", "OBSERVATION_MODIFIER", 135, 149], ["interference", "OBSERVATION", 150, 162], ["low prevalence", "OBSERVATION_MODIFIER", 192, 206]]], ["In addition, the prevalence of PTSD was significantly higher in the elderly and residents in SARS epidemic areas [30].", [["PTSD", "DISEASE", 31, 35], ["SARS", "DISEASE", 93, 97], ["PTSD", "PROBLEM", 31, 35], ["SARS epidemic areas", "PROBLEM", 93, 112], ["significantly", "OBSERVATION_MODIFIER", 40, 53], ["higher", "OBSERVATION_MODIFIER", 54, 60]]], ["The most relevant predictor is the financial stress caused by reduced income after illness, and other items included gender, range of activities, dietary restrictions, travel restrictions, clothing disinfection and infection control [31].", [["infection", "DISEASE", 215, 224], ["illness", "PROBLEM", 83, 90], ["dietary restrictions", "TREATMENT", 146, 166], ["clothing disinfection", "TREATMENT", 189, 210], ["infection control", "TREATMENT", 215, 232]]], ["These different pressures are highly correlated with the psychological stress index, so the causes of psychological problems are not only isolated factors.", [["These different pressures", "TEST", 0, 25], ["the psychological stress index", "TEST", 53, 83], ["psychological problems", "PROBLEM", 102, 124], ["different", "OBSERVATION_MODIFIER", 6, 15], ["pressures", "OBSERVATION_MODIFIER", 16, 25]]], ["During one-year follow-up period, evidence showed that both women and medical staff were risk factors for mental maladjustment.", [["maladjustment", "DISEASE", 113, 126], ["women", "ORGANISM", 60, 65], ["women", "SPECIES", 60, 65], ["mental maladjustment", "PROBLEM", 106, 126]]], ["Female survivors had higher stress levels, more severe depression and anxiety, and more severe post-traumatic stress symptoms, and their GHQ-12 scores were three times higher than that of men.", [["depression", "DISEASE", 55, 65], ["anxiety", "DISEASE", 70, 77], ["men", "ORGANISM", 188, 191], ["men", "SPECIES", 188, 191], ["higher stress levels", "PROBLEM", 21, 41], ["more severe depression", "PROBLEM", 43, 65], ["anxiety", "PROBLEM", 70, 77], ["more severe post-traumatic stress symptoms", "PROBLEM", 83, 125], ["their GHQ", "TEST", 131, 140], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["depression", "OBSERVATION", 55, 65], ["severe", "OBSERVATION_MODIFIER", 88, 94]]], ["Among them, women and participants with low education level are more likely to have avoidance symptoms [7].", [["women", "ORGANISM", 12, 17], ["women", "SPECIES", 12, 17], ["participants", "SPECIES", 22, 34], ["avoidance symptoms", "PROBLEM", 84, 102]]], ["In a study of college students, the number of stressors and the use of avoidance strategies can positively predict psychological symptoms [32] .", [["avoidance strategies", "TREATMENT", 71, 91], ["psychological symptoms", "PROBLEM", 115, 137]]], ["Therefore, in the face of large-scale stressors such as COVID-19, increasing psychological counseling and treatment services will be of great significance.High risk factors of mental disorders caused by COVID-19 ::: BackgroundWe found that the high-risk factors for the prognosis of patients with COVID-19 are not only related to the specific population, but also highly related to the treatment drugs in the acute phase.", [["mental disorders", "DISEASE", 176, 192], ["COVID-19", "CHEMICAL", 203, 211], ["COVID-19", "CHEMICAL", 297, 305], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["large-scale stressors", "PROBLEM", 26, 47], ["COVID", "TEST", 56, 61], ["increasing psychological counseling", "TREATMENT", 66, 101], ["treatment services", "TREATMENT", 106, 124], ["mental disorders", "PROBLEM", 176, 192], ["COVID", "TEST", 297, 302], ["the specific population", "PROBLEM", 330, 353], ["the treatment drugs", "TREATMENT", 382, 401], ["large", "OBSERVATION_MODIFIER", 26, 31], ["population", "OBSERVATION", 343, 353]]], ["For example, the use of a large number of interferon in the treatment of coronavirus will lead to emotional depression, anxiety, short-term memory disorders of sleep disorders through the impact on endocrine and changes in neurotransmitter and immune system changes [34]; meanwhile, high dose of exogenous steroids can cause reversible memory damage through the effect on hippocampal metabolism [35].The necessity of prevention of mental disorders in COVID-19 patients ::: BackgroundFrom the current situation of transmission, we are concerned about the mental state of people around the world.", [["endocrine", "ANATOMY", 198, 207], ["immune system", "ANATOMY", 244, 257], ["hippocampal", "ANATOMY", 372, 383], ["interferon", "CHEMICAL", 42, 52], ["coronavirus", "DISEASE", 73, 84], ["depression", "DISEASE", 108, 118], ["anxiety", "DISEASE", 120, 127], ["memory disorders", "DISEASE", 140, 156], ["sleep disorders", "DISEASE", 160, 175], ["steroids", "CHEMICAL", 306, 314], ["memory damage", "DISEASE", 336, 349], ["steroids", "CHEMICAL", 306, 314], ["interferon", "GENE_OR_GENE_PRODUCT", 42, 52], ["coronavirus", "ORGANISM", 73, 84], ["endocrine", "ANATOMICAL_SYSTEM", 198, 207], ["steroids", "SIMPLE_CHEMICAL", 306, 314], ["hippocampal", "MULTI-TISSUE_STRUCTURE", 372, 383], ["patients", "ORGANISM", 460, 468], ["people", "ORGANISM", 570, 576], ["interferon", "PROTEIN", 42, 52], ["patients", "SPECIES", 460, 468], ["people", "SPECIES", 570, 576], ["interferon", "TREATMENT", 42, 52], ["coronavirus", "PROBLEM", 73, 84], ["emotional depression", "PROBLEM", 98, 118], ["anxiety", "PROBLEM", 120, 127], ["short-term memory disorders", "PROBLEM", 129, 156], ["sleep disorders", "PROBLEM", 160, 175], ["immune system changes", "PROBLEM", 244, 265], ["exogenous steroids", "TREATMENT", 296, 314], ["reversible memory damage", "PROBLEM", 325, 349], ["mental disorders", "PROBLEM", 431, 447], ["large", "OBSERVATION_MODIFIER", 26, 31], ["reversible", "OBSERVATION_MODIFIER", 325, 335], ["memory damage", "OBSERVATION", 336, 349]]], ["With regard to SARS, whose outbreak was brought under control in a few months mainly due to the two characteristics of SARS coronavirus: First, coronavirus is a large virus and is not easy to mutate; second, the infected people show obvious symptoms when they are likely to spread the disease, so they can be identified and isolated in time [12].", [["SARS", "DISEASE", 15, 19], ["SARS coronavirus", "DISEASE", 119, 135], ["SARS coronavirus", "ORGANISM", 119, 135], ["coronavirus", "ORGANISM", 144, 155], ["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227], ["SARS coronavirus", "SPECIES", 119, 135], ["SARS", "PROBLEM", 15, 19], ["SARS coronavirus", "PROBLEM", 119, 135], ["coronavirus", "PROBLEM", 144, 155], ["a large virus", "PROBLEM", 159, 172], ["obvious symptoms", "PROBLEM", 233, 249], ["the disease", "PROBLEM", 281, 292], ["SARS", "OBSERVATION", 15, 19], ["coronavirus", "OBSERVATION", 144, 155], ["large", "OBSERVATION_MODIFIER", 161, 166], ["virus", "OBSERVATION", 167, 172], ["disease", "OBSERVATION", 285, 292]]], ["However, for this new coronavirus disease, the mutation of the virus is currently unknown, but some studies believe that novel coronavirus in different regions has some genetic differences.", [["coronavirus disease", "DISEASE", 22, 41], ["coronavirus", "DISEASE", 127, 138], ["coronavirus", "ORGANISM", 22, 33], ["coronavirus", "ORGANISM", 127, 138], ["this new coronavirus disease", "PROBLEM", 13, 41], ["the mutation of the virus", "PROBLEM", 43, 68], ["some studies", "TEST", 95, 107], ["novel coronavirus in different regions", "PROBLEM", 121, 159], ["new", "OBSERVATION_MODIFIER", 18, 21], ["coronavirus disease", "OBSERVATION", 22, 41], ["coronavirus", "OBSERVATION", 127, 138]]], ["Furthermore, Zhong Nanshan believes that the longest incubation period of coronavirus is 21 days, with an average incubation period of 7 days [36].", [["coronavirus", "DISEASE", 74, 85], ["coronavirus", "ORGANISM", 74, 85], ["coronavirus", "PROBLEM", 74, 85]]], ["A large number of asymptomatic cases have been reported in many countries, which has brought great difficulties to identification and isolation while greatly increasing anxiety and fear in people.", [["anxiety", "DISEASE", 169, 176], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 189, 195], ["asymptomatic cases", "PROBLEM", 18, 36], ["greatly increasing anxiety", "PROBLEM", 150, 176], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["cases", "OBSERVATION", 31, 36]]], ["For these patients with severe acute respiratory syndrome, the dread of this new type of fatal infectious disease, the fear of relatives and friends\u2019 infection, the experience of witnessing adverse events during hospitalization, the uncertainty of prognosis, and the nursing experience in Intensive care unit (ICU) are all terrible experiences.", [["acute respiratory syndrome", "DISEASE", 31, 57], ["infectious disease", "DISEASE", 95, 113], ["infection", "DISEASE", 150, 159], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["severe acute respiratory syndrome", "PROBLEM", 24, 57], ["fatal infectious disease", "PROBLEM", 89, 113], ["witnessing adverse events", "PROBLEM", 179, 204], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["respiratory syndrome", "OBSERVATION", 37, 57], ["fatal", "OBSERVATION_MODIFIER", 89, 94], ["infectious", "OBSERVATION", 95, 105]]], ["Under an overburdened medical system, followed by the contagion of stress in special occupational groups, especially for medical workers, inadequate personal protective equipment, unsystematic isolation process, and inactive disease control will make fear spread rapidly among individuals [12].Treatment suggestions for improving social psychological prognosis ::: BackgroundPsychological intervention is very necessary for patients, health care workers and the general public.", [["patients", "ORGANISM", 424, 432], ["patients", "SPECIES", 424, 432], ["unsystematic isolation process", "TREATMENT", 180, 210], ["inactive disease control", "PROBLEM", 216, 240], ["BackgroundPsychological intervention", "TREATMENT", 365, 401]]], ["We should pay attention to the high-risk groups prone to disease, and at the same time eliminate the stimulation factors that induce PTSD and depression as much as possible, and timely and early intervention is beneficial to reduce the incidence of PTSD [37].", [["PTSD", "DISEASE", 133, 137], ["depression", "DISEASE", 142, 152], ["PTSD", "DISEASE", 249, 253], ["disease", "PROBLEM", 57, 64], ["the stimulation factors", "PROBLEM", 97, 120], ["PTSD", "PROBLEM", 133, 137], ["depression", "PROBLEM", 142, 152], ["PTSD", "PROBLEM", 249, 253]]], ["We should not be overly pessimistic the prognosis of patients with COVID-19, although part of the source of mental illness is poor prognosis [4].", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["COVID", "TEST", 67, 72], ["mental illness", "PROBLEM", 108, 122]]], ["For some drugs that cause long-term adverse physical conditions, such as hormones [35], they are abandoned or restricted in the treatment guidelines of COVID-19, and according to all materials known on PubMed, the newly add drugs have no clear long-term impact.", [["some drugs", "TREATMENT", 4, 14], ["long-term adverse physical conditions", "PROBLEM", 26, 63], ["COVID", "TREATMENT", 152, 157], ["drugs", "TREATMENT", 224, 229], ["clear long-term impact", "PROBLEM", 238, 260], ["long-term", "OBSERVATION_MODIFIER", 26, 35], ["long-term impact", "OBSERVATION_MODIFIER", 244, 260]]], ["According to statistics, effective antidepressants such as chronic antidepressants can greatly reduce the degree of depression and anxiety symptoms [38], its chronic effect is related to the repair and possible construction of injured neural network; moreover, it can promote the growth of axons and dendrites [39], and may also play a role in the organ injury caused by chronic inflammation.", [["neural network", "ANATOMY", 235, 249], ["axons", "ANATOMY", 290, 295], ["dendrites", "ANATOMY", 300, 309], ["organ", "ANATOMY", 348, 353], ["antidepressants", "CHEMICAL", 35, 50], ["antidepressants", "CHEMICAL", 67, 82], ["depression", "DISEASE", 116, 126], ["anxiety", "DISEASE", 131, 138], ["organ injury", "DISEASE", 348, 360], ["inflammation", "DISEASE", 379, 391], ["neural network", "MULTI-TISSUE_STRUCTURE", 235, 249], ["axons", "CELLULAR_COMPONENT", 290, 295], ["organ", "ORGAN", 348, 353], ["effective antidepressants", "TREATMENT", 25, 50], ["chronic antidepressants", "TREATMENT", 59, 82], ["depression", "PROBLEM", 116, 126], ["anxiety symptoms", "PROBLEM", 131, 147], ["its chronic effect", "PROBLEM", 154, 172], ["the repair", "TREATMENT", 187, 197], ["injured neural network", "PROBLEM", 227, 249], ["the organ injury", "PROBLEM", 344, 360], ["chronic inflammation", "PROBLEM", 371, 391], ["repair", "OBSERVATION", 191, 197], ["organ", "ANATOMY", 348, 353], ["injury", "OBSERVATION", 354, 360], ["chronic", "OBSERVATION_MODIFIER", 371, 378], ["inflammation", "OBSERVATION", 379, 391]]], ["However, we are concerned about the psychological status of medical workers in some countries, because some studies have shown that during the outbreak, medical workers experienced anxiety, depression and poor sleep.", [["anxiety", "DISEASE", 181, 188], ["depression", "DISEASE", 190, 200], ["some studies", "TEST", 103, 115], ["anxiety", "PROBLEM", 181, 188], ["depression", "PROBLEM", 190, 200], ["poor sleep", "PROBLEM", 205, 215]]], ["Such situation began to improve 2 weeks after the adoption of SARS prevention and control measures, and systematic SARS prevention plan improved the mental state of medical workers [40].", [["SARS", "DISEASE", 62, 66], ["SARS", "DISEASE", 115, 119], ["SARS prevention", "TREATMENT", 62, 77], ["control measures", "TREATMENT", 82, 98], ["systematic SARS prevention", "TREATMENT", 104, 130]]], ["At the same time, the country\u2019s active and timely resource scheduling and integration is particularly important, and ecouraging the health care workers and improving the long-term potential for adverse mental health conditions is an important part of the country\u2019s response to the epidemic [41].Treatment suggestions for improving social psychological prognosis ::: BackgroundIt should be noted that stigmatization of disease may have a longer-term impact than disease itself.", [["adverse mental health conditions", "PROBLEM", 194, 226], ["stigmatization of disease", "PROBLEM", 400, 425], ["a longer-term impact than disease itself", "PROBLEM", 435, 475], ["disease", "OBSERVATION", 418, 425], ["longer-term impact", "OBSERVATION_MODIFIER", 437, 455]]], ["Two thousand three SARS virus, HIV and Spanish influenza, which was mistakenly associated with Spanish people, all of them have caused huge psychological and economic losses to specific groups and regions.", [["SARS virus, HIV and Spanish influenza", "DISEASE", 19, 56], ["HIV", "ORGANISM", 31, 34], ["people", "ORGANISM", 103, 109], ["HIV", "SPECIES", 31, 34], ["people", "SPECIES", 103, 109], ["SARS virus", "SPECIES", 19, 29], ["HIV", "SPECIES", 31, 34], ["Two thousand three SARS virus", "PROBLEM", 0, 29], ["HIV", "PROBLEM", 31, 34], ["Spanish influenza", "PROBLEM", 39, 56], ["huge psychological and economic losses to specific groups and regions", "PROBLEM", 135, 204], ["SARS virus", "OBSERVATION", 19, 29], ["huge", "OBSERVATION_MODIFIER", 135, 139]]], ["The stigmatization of diseases, especially of certain ethnic groups, can lead to adverse social emotions and promote racism.", [["adverse social emotions", "DISEASE", 81, 104], ["diseases", "PROBLEM", 22, 30], ["stigmatization", "OBSERVATION", 4, 18], ["diseases", "OBSERVATION", 22, 30]]], ["In 2006, don C. des jarlais PhD proposed a positive and effective strategy for the United States to remove the stigma of Acquired Immune Deficiency Syndrome (AIDS) and protect people suffering from AIDS, such as the President of the United States posing with AIDS patients, and the promulgation of the Americans with Disabilities Act [42].", [["Acquired Immune Deficiency Syndrome", "DISEASE", 121, 156], ["AIDS", "DISEASE", 158, 162], ["AIDS", "DISEASE", 198, 202], ["AIDS", "DISEASE", 259, 263], ["people", "ORGANISM", 176, 182], ["patients", "ORGANISM", 264, 272], ["people", "SPECIES", 176, 182], ["patients", "SPECIES", 264, 272], ["Acquired Immune Deficiency Syndrome", "PROBLEM", 121, 156], ["Immune Deficiency", "OBSERVATION", 130, 147]]], ["It is the common goal for all countries to pay attention to the prevention and treatment of diseases and take measures to protect the patients and it is also a task for every country to remove the stigma of disease.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["the prevention", "TREATMENT", 60, 74], ["diseases", "PROBLEM", 92, 100], ["disease", "PROBLEM", 207, 214], ["disease", "OBSERVATION", 207, 214]]], ["Therefore, in the COVID-19 treatment and prognosis stage, evaluation of psychological problems requires flexible skills due to subjects\u2019 fear of stigmatisation.Treatment suggestions for improving social psychological prognosis ::: BackgroundGenerally speaking, it is of great significance to carry out active and effective mental health education for the whole people, popularize relevant mental education assistance work as soon as possible, and provide timely psychological support with self-coping strategies to enhance their resilience and reduce their fear, anxiety and pressure.", [["stigmatisation", "DISEASE", 145, 159], ["anxiety", "DISEASE", 563, 570], ["people", "ORGANISM", 361, 367], ["people", "SPECIES", 361, 367], ["the COVID-19 treatment", "TREATMENT", 14, 36], ["evaluation", "TEST", 58, 68], ["psychological problems", "PROBLEM", 72, 94], ["stigmatisation", "PROBLEM", 145, 159], ["self-coping strategies", "TREATMENT", 489, 511], ["anxiety", "PROBLEM", 563, 570], ["pressure", "TEST", 575, 583]]], ["At the same time, it is more important to ensure the psychological status of specific occupations and high-risk groups, and the possibility of long-term subjective pain and occupational difficulties for medical workers infected with COVID-19 could be included in the data model, which will provide a better basis for future prevention and treatment [42].", [["pain", "DISEASE", 164, 168], ["long-term subjective pain", "PROBLEM", 143, 168], ["occupational difficulties", "PROBLEM", 173, 198], ["COVID", "TREATMENT", 233, 238], ["treatment", "TREATMENT", 339, 348]]], ["Effective prior preparation, such as effective risk communication and the provision of psychological first aid before psychological stress and behavioral symptoms, can improve the effectiveness of post disaster intervention [12].", [["Effective prior preparation", "TREATMENT", 0, 27], ["psychological first aid", "TREATMENT", 87, 110], ["psychological stress", "PROBLEM", 118, 138], ["behavioral symptoms", "PROBLEM", 143, 162], ["post disaster intervention", "TREATMENT", 197, 223]]], ["In addition, further longitudinal follow-up study on survivors can timely assess their mental consequences and determine the relationship between patients and their families\u2019 mental health, and it is also an important way to prevent and early correct patients\u2019 psychological and social stress during the follow-up period, and can provide a strong basis and reference for future emergent events.ConclusionThe mental and psychological impact of major public health events may be long-term and even far outweigh the initial threat to life.", [["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 251, 259], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 251, 259], ["further longitudinal follow-up study", "TEST", 13, 49], ["survivors", "TREATMENT", 53, 62]]], ["The psychological symptoms of COVID-19 patients and cured survivors include poor sleep quality, low mood, anxiety, inattention, and two of the most common and severe long-term mental illnesses-depression and PSTD, which will cause great burden and threat to society in the long run.", [["COVID", "DISEASE", 30, 35], ["low mood", "DISEASE", 96, 104], ["anxiety", "DISEASE", 106, 113], ["inattention", "DISEASE", 115, 126], ["depression", "DISEASE", 193, 203], ["PSTD", "DISEASE", 208, 212], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["The psychological symptoms", "PROBLEM", 0, 26], ["COVID", "TEST", 30, 35], ["poor sleep quality", "PROBLEM", 76, 94], ["low mood", "PROBLEM", 96, 104], ["anxiety", "PROBLEM", 106, 113], ["inattention", "PROBLEM", 115, 126], ["severe long-term mental illnesses", "PROBLEM", 159, 192], ["depression", "PROBLEM", 193, 203], ["PSTD", "PROBLEM", 208, 212], ["great burden", "PROBLEM", 231, 243], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["long-term", "OBSERVATION_MODIFIER", 166, 175]]], ["Age, gender, incidence rate and risk factors of acute phase are highly correlated with psychological morbidity, thereby providing a reliable basis for early identification and psychological support.", [["acute phase", "PROBLEM", 48, 59], ["psychological morbidity", "PROBLEM", 87, 110], ["psychological support", "TREATMENT", 176, 197], ["acute", "OBSERVATION_MODIFIER", 48, 53]]], ["At the same time, medical staff, as a special group fighting against epidemics and susceptible to infection, are facing multiple and complex pressures and are more prone to mental and psychological diseases, especially in the infected medical staff.", [["infection", "DISEASE", 98, 107], ["epidemics", "PROBLEM", 69, 78], ["infection", "PROBLEM", 98, 107], ["mental and psychological diseases", "PROBLEM", 173, 206], ["infection", "OBSERVATION", 98, 107], ["complex", "OBSERVATION_MODIFIER", 133, 140], ["pressures", "OBSERVATION_MODIFIER", 141, 150]]], ["Inflammatory response and other organ system prognosis sequelae are the possible mechanism for the generation and continuous progression of depression and PSTD.", [["organ system", "ANATOMY", 32, 44], ["depression", "DISEASE", 140, 150], ["PSTD", "DISEASE", 155, 159], ["organ", "ORGAN", 32, 37], ["Inflammatory response", "PROBLEM", 0, 21], ["other organ system prognosis sequelae", "PROBLEM", 26, 63], ["the generation", "PROBLEM", 95, 109], ["depression", "PROBLEM", 140, 150], ["PSTD", "PROBLEM", 155, 159], ["depression", "OBSERVATION", 140, 150]]], ["Therefore, it will exert a significant effect by reducing the dosage of corticosteroids in the treatment period, actively treating the psychiatric or psychological complications in the rehabilitation period with psychological counseling and treating severe cases of depression with chronic antidepressant medication.", [["corticosteroids", "CHEMICAL", 72, 87], ["psychiatric", "DISEASE", 135, 146], ["depression", "DISEASE", 266, 276], ["antidepressant", "CHEMICAL", 290, 304], ["corticosteroids", "CHEMICAL", 72, 87], ["corticosteroids", "TREATMENT", 72, 87], ["the psychiatric or psychological complications", "PROBLEM", 131, 177], ["psychological counseling", "TREATMENT", 212, 236], ["depression", "PROBLEM", 266, 276], ["chronic antidepressant medication", "TREATMENT", 282, 315]]], ["In addition, the government should provide public policy support to survivors, de-stigmatize the disease, and develop follow-up research programs to strengthen the evaluation of COVID-19 for long-term mental illness.", [["public policy support", "TREATMENT", 43, 64], ["the disease", "PROBLEM", 93, 104], ["the evaluation", "TEST", 160, 174], ["COVID", "TEST", 178, 183], ["long-term mental illness", "PROBLEM", 191, 215]]]], "PMC7473792": [["CONFLICTS OF INTERESTGuarantor of the article: Keith S. Sultan, MD.CONFLICTS OF INTERESTSpecific author contributions: All authors contributed to the writing and editing of this case report.CONFLICTS OF INTERESTPotential competing interests: None to report.CONFLICTS OF INTERESTFinancial support: None to report.CONFLICTS OF INTERESTIRB approval: This falls under our retrospective IRB for endoscopic research.CONFLICTS OF INTERESTConsent statement: The patient provided informed consent to discuss her case in this correspondence.", [["patient", "ORGANISM", 454, 461], ["patient", "SPECIES", 454, 461], ["our retrospective IRB", "TREATMENT", 364, 385], ["endoscopic research", "TEST", 390, 409]]]], "2282bdddc8cb18da2dea22769c05f86a3f24262c": [["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.66is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint 4 Information about the length-time of a consultation with a patient with MM is essential 67 to better organize and deliver healthcare.", [["CC", "CHEMICAL", 0, 2], ["MM", "DISEASE", 363, 365], ["patient", "ORGANISM", 350, 357], ["patient", "SPECIES", 350, 357], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 193, 213], ["this preprint", "TREATMENT", 218, 231], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["To our knowledge, no previous review has 68 summarized data related to: \"What is the impact of having MM on the medical consultation?\" 69 \"Is the average length-time consultation with a patient with MM longer than for a patient without CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.66is the (which was not peer-reviewed) The copyright holder for this preprint CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.66is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint124This systematic review was conducted using Covidence13, the standard production 125 platform used for Cochrane reviews, which was used for the data and records management.", [["MM", "DISEASE", 102, 104], ["CC", "CHEMICAL", 236, 238], ["CC", "CHEMICAL", 468, 470], ["MM", "CANCER", 102, 104], ["patient", "ORGANISM", 186, 193], ["patient", "ORGANISM", 220, 227], ["patient", "SPECIES", 186, 193], ["patient", "SPECIES", 220, 227], ["The copyright holder", "TREATMENT", 661, 681], ["this preprint", "TREATMENT", 686, 699], ["Cochrane reviews", "TEST", 861, 877], ["med", "ANATOMY", 334, 337], ["med", "ANATOMY", 566, 569]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.124is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.124is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint 8149The main relevant features and outputs of the study were extracted for the purpose of 150 this systematic review and are summed up in Table 1 .151The included study was conducted between 2008 and 2009 in Denmark, over 12 152 months.", [["CC", "CHEMICAL", 0, 2], ["CC", "CHEMICAL", 290, 292], ["doi: medRxiv preprint 8149", "SPECIES", 558, 584], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 194, 214], ["this preprint", "TREATMENT", 219, 232], ["The copyright holder", "TREATMENT", 484, 504], ["this preprint", "TREATMENT", 509, 522], ["the study", "TEST", 626, 635], ["The included study", "TEST", 730, 748], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101], ["med", "ANATOMY", 388, 391], ["main", "OBSERVATION_MODIFIER", 588, 592], ["outputs", "OBSERVATION_MODIFIER", 615, 622]]], ["It involved 404 general practitioners (GPs) participants and a total of 8236 contacts.153It included patients aged 40 years or more, grouped as those without any chronic condition 154 and those with one, two, three or more chronic conditions.155During the study period, the GPs completed a one-page registration form for each of 156 their patient contacts.", [["patients", "ORGANISM", 101, 109], ["patient", "ORGANISM", 339, 346], ["participants", "SPECIES", 44, 56], ["patients", "SPECIES", 101, 109], ["patient", "SPECIES", 339, 346], ["any chronic condition", "PROBLEM", 158, 179], ["the study", "TEST", 252, 261], ["chronic", "OBSERVATION_MODIFIER", 223, 230], ["conditions", "OBSERVATION", 231, 241]]], ["Of the various items that were registered, the ones relevant forthis 157 review were information on chronic diseases and length-time of consultation.", [["chronic diseases", "PROBLEM", 100, 116]]], ["Quality 158 assessment result, performed as described in methodology, is presented in Table 2 .", [["Quality 158 assessment", "TEST", 0, 22]]], ["The 159 quality of the study was considered satisfactory (score 6 out of a maximum score of 10), its CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.155is the (which was not peer-reviewed) The copyright holder for this preprint .", [["CC", "CHEMICAL", 101, 103], ["the study", "TEST", 19, 28], ["a maximum score", "TEST", 73, 88], ["its CC", "TEST", 97, 103], ["NC", "TEST", 107, 109], ["The copyright holder", "TREATMENT", 295, 315], ["this preprint", "TREATMENT", 320, 333], ["med", "ANATOMY", 199, 202]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.155is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint205The present systematic review sought to answer the following question: \"Is the average242The data analysis must be evaluated using objective validated laboratory methods 243 and, if possible, it should be a blind assessment.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 194, 214], ["this preprint", "TREATMENT", 219, 232], ["medRxiv", "TREATMENT", 273, 280], ["The data analysis", "TEST", 381, 398], ["a blind assessment", "TEST", 497, 515], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["Statistical tests used to analyse the data 244 must be appropriate and clearly described.", [["Statistical tests", "TEST", 0, 17]]], ["Measures of association, including confidence 245 intervals and the P value, must be presented.246The main limitation of this systematic review was the difficulty in ensuring that all the 247 relevant literature was included.", [["the P value", "TEST", 64, 75], ["main", "OBSERVATION_MODIFIER", 102, 106], ["limitation", "OBSERVATION_MODIFIER", 107, 117]]], ["Even though the research used two of the main databases -248Pubmed and Embasethere could be other relevant material in grey literature.249The scarcity of the literature that was found was a limitation for this review.", [["the main databases", "TEST", 37, 55], ["this review", "TEST", 205, 216]]], ["The one258This \"impact of MM on the duration of a consultation\" has hardly been studied, this 259 systematic review shows.260A tendency for consultations of patients with MM to take longer than those without MM 261 was found in the only one study with \"satisfactory\" quality which met the inclusion criteria.295.", [["MM", "DISEASE", 26, 28], ["MM", "DISEASE", 171, 173], ["MM", "DISEASE", 208, 210], ["MM", "CANCER", 26, 28], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.295is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint No author states financial and non-financial competing interests for this work.402.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 194, 214], ["this preprint", "TREATMENT", 219, 232], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]], ["CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.402is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19007328 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 194, 214], ["this preprint", "TREATMENT", 219, 232], ["medRxiv", "TREATMENT", 273, 280], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 98, 101]]]], "PMC7148629": [], "PMC7457935": [["IntroductionSince its origination in Wuhan, China, COVID-19, which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) virus, has rapidly spread leading to a worldwide pandemic.", [["COVID-19", "CHEMICAL", 51, 59], ["acute respiratory syndrome coronavirus", "DISEASE", 91, 129], ["COVID-19", "CELL", 51, 59], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 84, 131], ["SARS CoV-2", "ORGANISM", 133, 143], ["CoV-2", "SPECIES", 138, 143], ["severe acute respiratory syndrome coronavirus", "SPECIES", 84, 129], ["SARS CoV-2) virus", "SPECIES", 133, 150], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 80, 129], ["SARS CoV", "TEST", 133, 141], ["virus", "PROBLEM", 145, 150], ["a worldwide pandemic", "PROBLEM", 182, 202], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome coronavirus", "OBSERVATION", 97, 129]]], ["There has been a growing interest in the role of hypercoagulability that has been demonstrated in COVID patients with many often presenting with diffuse thrombosis2.", [["hypercoagulability", "DISEASE", 49, 67], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["hypercoagulability", "PROBLEM", 49, 67], ["diffuse thrombosis2", "PROBLEM", 145, 164], ["growing", "OBSERVATION_MODIFIER", 17, 24], ["interest", "OBSERVATION_MODIFIER", 25, 33], ["hypercoagulability", "OBSERVATION", 49, 67], ["diffuse", "OBSERVATION_MODIFIER", 145, 152], ["thrombosis2", "OBSERVATION", 153, 164]]], ["Some of the thrombotic disease has manifested as widespread micro emboli with a large clot burden leading to the morbidity and mortality seen with this disease.IntroductionAppropriate anticoagulation therapy has become the subject of much discussion and multiple hospitals have put forth institutional policies to address the initiation of anticoagulation in moderate to severe disease.", [["micro emboli", "ANATOMY", 60, 72], ["clot", "ANATOMY", 86, 90], ["thrombotic disease", "DISEASE", 12, 30], ["micro emboli", "DISEASE", 60, 72], ["micro emboli", "PATHOLOGICAL_FORMATION", 60, 72], ["clot", "ORGANISM_SUBSTANCE", 86, 90], ["the thrombotic disease", "PROBLEM", 8, 30], ["widespread micro emboli", "PROBLEM", 49, 72], ["a large clot burden", "PROBLEM", 78, 97], ["the morbidity", "PROBLEM", 109, 122], ["this disease", "PROBLEM", 147, 159], ["IntroductionAppropriate anticoagulation therapy", "TREATMENT", 160, 207], ["anticoagulation", "TREATMENT", 340, 355], ["moderate to severe disease", "PROBLEM", 359, 385], ["thrombotic", "OBSERVATION_MODIFIER", 12, 22], ["disease", "OBSERVATION", 23, 30], ["widespread", "OBSERVATION_MODIFIER", 49, 59], ["micro", "OBSERVATION_MODIFIER", 60, 65], ["emboli", "OBSERVATION", 66, 72], ["large", "OBSERVATION_MODIFIER", 80, 85], ["clot", "OBSERVATION", 86, 90], ["morbidity", "OBSERVATION", 113, 122], ["disease", "OBSERVATION", 152, 159], ["moderate", "OBSERVATION_MODIFIER", 359, 367], ["severe", "OBSERVATION_MODIFIER", 371, 377], ["disease", "OBSERVATION", 378, 385]]], ["However, it is unclear how many patients rapidly develop diffuse thrombus formation and what the optimal timing of therapy is.", [["thrombus", "ANATOMY", 65, 73], ["thrombus", "DISEASE", 65, 73], ["patients", "ORGANISM", 32, 40], ["diffuse thrombus", "PATHOLOGICAL_FORMATION", 57, 73], ["patients", "SPECIES", 32, 40], ["diffuse thrombus formation", "PROBLEM", 57, 83], ["therapy", "TREATMENT", 115, 122], ["diffuse", "OBSERVATION_MODIFIER", 57, 64], ["thrombus", "OBSERVATION", 65, 73]]], ["Thrombolytic therapy, i.e. tPA, may have a role in treating these patients, and may prevent further deterioration secondary to large clot burden.IntroductionThis manuscript adheres to the applicable EQUATOR guideline.", [["clot", "ANATOMY", 133, 137], ["tPA", "GENE_OR_GENE_PRODUCT", 27, 30], ["patients", "ORGANISM", 66, 74], ["clot", "ORGANISM_SUBSTANCE", 133, 137], ["patients", "SPECIES", 66, 74], ["Thrombolytic therapy", "TREATMENT", 0, 20], ["tPA", "TREATMENT", 27, 30], ["further deterioration", "PROBLEM", 92, 113], ["large clot burden", "PROBLEM", 127, 144], ["large", "OBSERVATION_MODIFIER", 127, 132], ["clot", "OBSERVATION", 133, 137]]], ["The appropriate HIPAA authorization was obtained from the patient's healthcare proxy for the submission of this report.Case ReportAn 81-year-old male with a history of hypertension, hyperlipidemia, gastric ulcer, aortic valve replacement, and chronic lymphocytic leukemia presented to the emergency room (ER) complaining of fever and cough for 10 days and new onset shortness of breath with chest pain for 24 hours.", [["gastric ulcer", "ANATOMY", 198, 211], ["aortic valve", "ANATOMY", 213, 225], ["chronic lymphocytic leukemia", "ANATOMY", 243, 271], ["chest", "ANATOMY", 391, 396], ["hypertension", "DISEASE", 168, 180], ["hyperlipidemia", "DISEASE", 182, 196], ["gastric ulcer", "DISEASE", 198, 211], ["chronic lymphocytic leukemia", "DISEASE", 243, 271], ["fever", "DISEASE", 324, 329], ["cough", "DISEASE", 334, 339], ["shortness of breath", "DISEASE", 366, 385], ["chest pain", "DISEASE", 391, 401], ["patient", "ORGANISM", 58, 65], ["male", "ORGANISM", 145, 149], ["gastric ulcer", "PATHOLOGICAL_FORMATION", 198, 211], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 213, 225], ["chronic lymphocytic leukemia", "CANCER", 243, 271], ["chest", "ORGANISM_SUBDIVISION", 391, 396], ["patient", "SPECIES", 58, 65], ["hypertension", "PROBLEM", 168, 180], ["hyperlipidemia", "PROBLEM", 182, 196], ["gastric ulcer", "PROBLEM", 198, 211], ["aortic valve replacement", "TREATMENT", 213, 237], ["chronic lymphocytic leukemia", "PROBLEM", 243, 271], ["fever", "PROBLEM", 324, 329], ["cough", "PROBLEM", 334, 339], ["new onset shortness of breath", "PROBLEM", 356, 385], ["chest pain", "PROBLEM", 391, 401], ["hypertension", "OBSERVATION", 168, 180], ["hyperlipidemia", "OBSERVATION", 182, 196], ["gastric", "ANATOMY", 198, 205], ["ulcer", "OBSERVATION", 206, 211], ["aortic valve", "ANATOMY", 213, 225], ["replacement", "OBSERVATION", 226, 237], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["lymphocytic leukemia", "OBSERVATION", 251, 271], ["fever", "OBSERVATION", 324, 329], ["cough", "OBSERVATION", 334, 339], ["chest", "ANATOMY", 391, 396]]], ["He had a mild lymphocytosis, elevated inflammatory markers (i.e. ferritin, C-reactive protein, lactate dehydrogenase, d-dimer, and procalcitonin), and bilateral opacities on chest radiograph.", [["chest", "ANATOMY", 174, 179], ["lymphocytosis", "DISEASE", 14, 27], ["lactate", "CHEMICAL", 95, 102], ["opacities", "DISEASE", 161, 170], ["lactate", "CHEMICAL", 95, 102], ["ferritin", "GENE_OR_GENE_PRODUCT", 65, 73], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 75, 93], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 95, 116], ["d-dimer", "SIMPLE_CHEMICAL", 118, 125], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 131, 144], ["inflammatory markers", "PROTEIN", 38, 58], ["ferritin", "PROTEIN", 65, 73], ["C-reactive protein", "PROTEIN", 75, 93], ["lactate dehydrogenase", "PROTEIN", 95, 116], ["d-dimer", "PROTEIN", 118, 125], ["procalcitonin", "PROTEIN", 131, 144], ["a mild lymphocytosis", "PROBLEM", 7, 27], ["elevated inflammatory markers", "PROBLEM", 29, 58], ["ferritin", "TEST", 65, 73], ["C-reactive protein", "PROBLEM", 75, 93], ["lactate dehydrogenase, d-dimer", "PROBLEM", 95, 125], ["procalcitonin", "TEST", 131, 144], ["bilateral opacities", "PROBLEM", 151, 170], ["chest radiograph", "TEST", 174, 190], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["lymphocytosis", "OBSERVATION", 14, 27], ["elevated", "OBSERVATION_MODIFIER", 29, 37], ["inflammatory markers", "OBSERVATION", 38, 58], ["reactive protein", "OBSERVATION", 77, 93], ["bilateral", "ANATOMY_MODIFIER", 151, 160], ["opacities", "OBSERVATION", 161, 170], ["chest", "ANATOMY", 174, 179]]], ["The patient was admitted with viral pneumonia due to moderate/severe COVID-191.", [["pneumonia", "DISEASE", 36, 45], ["COVID-191", "CHEMICAL", 69, 78], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["viral pneumonia", "PROBLEM", 30, 45], ["moderate/severe COVID", "PROBLEM", 53, 74], ["pneumonia", "OBSERVATION", 36, 45], ["moderate", "OBSERVATION_MODIFIER", 53, 61], ["severe", "OBSERVATION_MODIFIER", 62, 68]]], ["He was started on hydroxychloroquine, azithromycin and broad-spectrum antibiotics.", [["hydroxychloroquine", "CHEMICAL", 18, 36], ["azithromycin", "CHEMICAL", 38, 50], ["hydroxychloroquine", "CHEMICAL", 18, 36], ["azithromycin", "CHEMICAL", 38, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 18, 36], ["azithromycin", "SIMPLE_CHEMICAL", 38, 50], ["hydroxychloroquine", "TREATMENT", 18, 36], ["azithromycin", "TREATMENT", 38, 50], ["broad-spectrum antibiotics", "TREATMENT", 55, 81]]], ["While in the ER his oxygenation worsened on non-rebreather (NRB), he was transitioned to bilevel positive airway pressure (bipap) and screened into the intensive care unit (ICU).Case ReportOn admission to the ICU, methylprednisolone, aspirin, and subcutaneous heparin were added to his medication regimen.", [["ER", "ANATOMY", 13, 15], ["airway", "ANATOMY", 106, 112], ["subcutaneous", "ANATOMY", 247, 259], ["methylprednisolone", "CHEMICAL", 214, 232], ["aspirin", "CHEMICAL", 234, 241], ["heparin", "CHEMICAL", 260, 267], ["methylprednisolone", "CHEMICAL", 214, 232], ["aspirin", "CHEMICAL", 234, 241], ["ER", "GENE_OR_GENE_PRODUCT", 13, 15], ["airway", "MULTI-TISSUE_STRUCTURE", 106, 112], ["methylprednisolone", "SIMPLE_CHEMICAL", 214, 232], ["aspirin", "SIMPLE_CHEMICAL", 234, 241], ["heparin", "SIMPLE_CHEMICAL", 260, 267], ["ER", "PROTEIN", 13, 15], ["non-rebreather", "TREATMENT", 44, 58], ["NRB", "TREATMENT", 60, 63], ["bilevel positive airway pressure", "TREATMENT", 89, 121], ["bipap", "TREATMENT", 123, 128], ["methylprednisolone", "TREATMENT", 214, 232], ["aspirin", "TREATMENT", 234, 241], ["subcutaneous heparin", "TREATMENT", 247, 267], ["his medication regimen", "TREATMENT", 282, 304], ["oxygenation", "OBSERVATION_MODIFIER", 20, 31], ["worsened", "OBSERVATION_MODIFIER", 32, 40], ["airway pressure", "OBSERVATION", 106, 121]]], ["Due to frequent episodes of supraventricular tachycardia and atrial fibrillation, he was started on apixaban 5 mg daily per cardiology recommendation.", [["supraventricular", "ANATOMY", 28, 44], ["atrial", "ANATOMY", 61, 67], ["supraventricular tachycardia", "DISEASE", 28, 56], ["atrial fibrillation", "DISEASE", 61, 80], ["apixaban", "CHEMICAL", 100, 108], ["apixaban", "CHEMICAL", 100, 108], ["apixaban", "SIMPLE_CHEMICAL", 100, 108], ["supraventricular tachycardia", "PROBLEM", 28, 56], ["atrial fibrillation", "PROBLEM", 61, 80], ["apixaban", "TREATMENT", 100, 108], ["supraventricular tachycardia", "OBSERVATION", 28, 56], ["atrial", "ANATOMY", 61, 67], ["fibrillation", "OBSERVATION", 68, 80]]], ["His QTc rose to 538 and so the hydroxychloroquine was discontinued.", [["hydroxychloroquine", "CHEMICAL", 31, 49], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["His QTc", "TEST", 0, 7], ["the hydroxychloroquine", "TREATMENT", 27, 49]]], ["Additionally, the patient began self-proning daily for 8 hour shifts with no appreciable improvement.Case ReportOn admission day 6, the patient received as dose of tocilizumab for an elevated interleukin-6 level and therapeutic enoxaparin was started in place of apixaban due to concern for insufficient anticoagulation.", [["tocilizumab", "CHEMICAL", 164, 175], ["enoxaparin", "CHEMICAL", 228, 238], ["apixaban", "CHEMICAL", 263, 271], ["enoxaparin", "CHEMICAL", 228, 238], ["apixaban", "CHEMICAL", 263, 271], ["patient", "ORGANISM", 18, 25], ["patient", "ORGANISM", 136, 143], ["tocilizumab", "SIMPLE_CHEMICAL", 164, 175], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 192, 205], ["enoxaparin", "SIMPLE_CHEMICAL", 228, 238], ["apixaban", "SIMPLE_CHEMICAL", 263, 271], ["interleukin-6", "PROTEIN", 192, 205], ["patient", "SPECIES", 18, 25], ["patient", "SPECIES", 136, 143], ["tocilizumab", "TREATMENT", 164, 175], ["an elevated interleukin", "PROBLEM", 180, 203], ["therapeutic enoxaparin", "TREATMENT", 216, 238], ["apixaban", "TREATMENT", 263, 271], ["insufficient anticoagulation", "TREATMENT", 291, 319], ["no", "UNCERTAINTY", 74, 76], ["appreciable", "OBSERVATION_MODIFIER", 77, 88], ["improvement", "OBSERVATION", 89, 100], ["anticoagulation", "OBSERVATION", 304, 319]]], ["However, he continued to decompensate with persistent hypoxia (partial pressure of arterial oxygen (PaO2) of 43 mmHg on 100% fraction of inspired oxygen (FiO2) on bipap), worsening respiratory distress and was intubated on day 7.", [["arterial", "ANATOMY", 83, 91], ["respiratory", "ANATOMY", 181, 192], ["hypoxia", "DISEASE", 54, 61], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "CHEMICAL", 146, 152], ["respiratory distress", "DISEASE", 181, 201], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "CHEMICAL", 146, 152], ["FiO2", "CHEMICAL", 154, 158], ["arterial", "MULTI-TISSUE_STRUCTURE", 83, 91], ["oxygen", "SIMPLE_CHEMICAL", 92, 98], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["FiO2", "SIMPLE_CHEMICAL", 154, 158], ["persistent hypoxia", "PROBLEM", 43, 61], ["arterial oxygen", "TEST", 83, 98], ["PaO2", "TEST", 100, 104], ["inspired oxygen (FiO2", "TREATMENT", 137, 158], ["bipap", "TREATMENT", 163, 168], ["worsening respiratory distress", "PROBLEM", 171, 201], ["intubated", "TREATMENT", 210, 219], ["persistent", "OBSERVATION_MODIFIER", 43, 53], ["hypoxia", "OBSERVATION", 54, 61], ["partial", "OBSERVATION_MODIFIER", 63, 70], ["pressure", "OBSERVATION_MODIFIER", 71, 79], ["arterial", "ANATOMY_MODIFIER", 83, 91], ["worsening", "OBSERVATION_MODIFIER", 171, 180], ["respiratory distress", "OBSERVATION", 181, 201]]], ["After intubation, his oxygenation initially improved on ventilator settings with tidal volumes of 400 mL, respiratory rates of 22, positive end expiratory pressure (PEEP) of 12, and FiO2 of 100%.", [["intubation", "TREATMENT", 6, 16], ["his oxygenation", "TEST", 18, 33], ["ventilator settings", "TREATMENT", 56, 75], ["tidal volumes", "TEST", 81, 94], ["respiratory rates", "TEST", 106, 123], ["positive end expiratory pressure", "TEST", 131, 163], ["PEEP", "TEST", 165, 169], ["FiO2", "TEST", 182, 186], ["improved", "OBSERVATION_MODIFIER", 44, 52], ["expiratory pressure", "OBSERVATION", 144, 163]]], ["However, dead space ventilation was apparent with a persistent hypercarbia and alveolar pressures of 12-15 mmHg.", [["alveolar", "ANATOMY", 79, 87], ["hypercarbia", "DISEASE", 63, 74], ["alveolar", "MULTI-TISSUE_STRUCTURE", 79, 87], ["dead space ventilation", "TEST", 9, 31], ["a persistent hypercarbia", "PROBLEM", 50, 74], ["alveolar pressures", "TEST", 79, 97], ["dead", "OBSERVATION", 9, 13], ["space ventilation", "OBSERVATION", 14, 31], ["persistent", "OBSERVATION_MODIFIER", 52, 62], ["hypercarbia", "OBSERVATION", 63, 74], ["alveolar", "ANATOMY_MODIFIER", 79, 87], ["pressures", "OBSERVATION_MODIFIER", 88, 97]]], ["Due to recent respiratory deterioration and suspicion for diffuse pulmonary microthrombi, tPA was administered without further workup or diagnostic studies.", [["respiratory", "ANATOMY", 14, 25], ["pulmonary", "ANATOMY", 66, 75], ["respiratory deterioration", "DISEASE", 14, 39], ["pulmonary", "ORGAN", 66, 75], ["tPA", "GENE_OR_GENE_PRODUCT", 90, 93], ["tPA", "PROTEIN", 90, 93], ["recent respiratory deterioration", "PROBLEM", 7, 39], ["diffuse pulmonary microthrombi", "PROBLEM", 58, 88], ["tPA", "TREATMENT", 90, 93], ["further workup", "TEST", 119, 133], ["diagnostic studies", "TEST", 137, 155], ["respiratory", "ANATOMY", 14, 25], ["deterioration", "OBSERVATION", 26, 39], ["suspicion for", "UNCERTAINTY", 44, 57], ["diffuse", "OBSERVATION_MODIFIER", 58, 65], ["pulmonary", "ANATOMY", 66, 75], ["microthrombi", "OBSERVATION", 76, 88]]], ["The dose administered was a 6 mg bolus and 2 mg per hour infusion over 22 hours.Case ReportDuring the thrombolytic infusion, the P/F (PaO2/FiO2) ratio improved to 142 (PaO2 of 114 mmHg on a FiO2 of 80%) on day 8.", [["the thrombolytic infusion", "TREATMENT", 98, 123], ["the P/F", "TEST", 125, 132], ["PaO2/FiO2", "TEST", 134, 143], ["ratio", "TEST", 145, 150], ["PaO2", "TEST", 168, 172], ["a FiO2", "TEST", 188, 194]]], ["After completion of the tPA infusion the patient was started on a heparin infusion.", [["heparin", "CHEMICAL", 66, 73], ["tPA", "GENE_OR_GENE_PRODUCT", 24, 27], ["patient", "ORGANISM", 41, 48], ["heparin", "SIMPLE_CHEMICAL", 66, 73], ["tPA", "PROTEIN", 24, 27], ["patient", "SPECIES", 41, 48], ["the tPA infusion", "TREATMENT", 20, 36], ["a heparin infusion", "TREATMENT", 64, 82]]], ["By day 9, his ventilator was weaned to a FiO2 of 40%, he tolerated a spontaneous breathing trial and was extubated to bipap at 40%.", [["his ventilator", "TREATMENT", 10, 24], ["a FiO2", "TREATMENT", 39, 45], ["a spontaneous breathing trial", "TREATMENT", 67, 96], ["bipap", "TREATMENT", 118, 123]]], ["Arterial blood gas showed resolution of the dead space ventilation (partial pressure of arterial carbon dioxide (PaCO2) of 30.5 mmHg) and his P/F ratio drastically increased to 610 (PaO2 of 244 mmHg on a FiO2 of 40%).", [["Arterial blood", "ANATOMY", 0, 14], ["arterial", "ANATOMY", 88, 96], ["carbon dioxide", "CHEMICAL", 97, 111], ["carbon dioxide", "CHEMICAL", 97, 111], ["PaCO2", "CHEMICAL", 113, 118], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["arterial", "MULTI-TISSUE_STRUCTURE", 88, 96], ["Arterial blood gas", "TEST", 0, 18], ["the dead space ventilation", "TREATMENT", 40, 66], ["arterial carbon dioxide", "TEST", 88, 111], ["PaCO2", "TEST", 113, 118], ["his P/F ratio", "TEST", 138, 151], ["PaO2", "TEST", 182, 186], ["a FiO2", "TEST", 202, 208], ["resolution", "OBSERVATION_MODIFIER", 26, 36], ["dead space ventilation", "OBSERVATION", 44, 66], ["pressure", "OBSERVATION_MODIFIER", 76, 84]]], ["Table 1summarizes pulmonary and arterial gas measurements around the time of tPA administration.", [["pulmonary", "ANATOMY", 18, 27], ["arterial", "ANATOMY", 32, 40], ["pulmonary", "ORGAN", 18, 27], ["arterial", "MULTI-TISSUE_STRUCTURE", 32, 40], ["tPA", "GENE_OR_GENE_PRODUCT", 77, 80], ["tPA", "PROTEIN", 77, 80], ["arterial gas measurements", "TEST", 32, 57], ["tPA administration", "TREATMENT", 77, 95], ["pulmonary", "ANATOMY", 18, 27], ["arterial", "ANATOMY", 32, 40]]], ["D-dimers, elevated at 2.8 upon presentation, increased to 16.91 after initiation of tPA before trending downwards.", [["D-dimers", "GENE_OR_GENE_PRODUCT", 0, 8], ["tPA", "GENE_OR_GENE_PRODUCT", 84, 87], ["tPA", "PROTEIN", 84, 87], ["D-dimers", "TEST", 0, 8], ["elevated", "PROBLEM", 10, 18], ["tPA", "TREATMENT", 84, 87], ["elevated", "OBSERVATION_MODIFIER", 10, 18]]], ["However, the lytic and anticoagulation treatment was complicated by melena consistent with an upper gastrointestinal bleed.", [["gastrointestinal", "ANATOMY", 100, 116], ["melena", "DISEASE", 68, 74], ["upper gastrointestinal bleed", "DISEASE", 94, 122], ["melena", "PATHOLOGICAL_FORMATION", 68, 74], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 94, 116], ["anticoagulation treatment", "TREATMENT", 23, 48], ["melena", "PROBLEM", 68, 74], ["an upper gastrointestinal bleed", "PROBLEM", 91, 122], ["lytic", "OBSERVATION_MODIFIER", 13, 18], ["melena", "OBSERVATION", 68, 74], ["consistent with", "UNCERTAINTY", 75, 90], ["upper", "ANATOMY_MODIFIER", 94, 99], ["gastrointestinal", "ANATOMY", 100, 116], ["bleed", "OBSERVATION", 117, 122]]], ["After discontinuation of heparin and aspirin, 2 units of packed red blood cells were given to treat an acute blood loss anemia.", [["red blood cells", "ANATOMY", 64, 79], ["blood", "ANATOMY", 109, 114], ["heparin", "CHEMICAL", 25, 32], ["aspirin", "CHEMICAL", 37, 44], ["blood loss", "DISEASE", 109, 119], ["anemia", "DISEASE", 120, 126], ["aspirin", "CHEMICAL", 37, 44], ["heparin", "SIMPLE_CHEMICAL", 25, 32], ["aspirin", "SIMPLE_CHEMICAL", 37, 44], ["red blood cells", "CELL", 64, 79], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["packed red blood cells", "CELL_TYPE", 57, 79], ["heparin", "TREATMENT", 25, 32], ["aspirin", "TREATMENT", 37, 44], ["packed red blood cells", "TREATMENT", 57, 79], ["an acute blood loss anemia", "PROBLEM", 100, 126], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["blood loss", "OBSERVATION", 109, 119]]], ["He transitioned to NRB over the next few days, was transferred out of the ICU on day 13 and discharged on day 28.DiscussionIn COVID-19, caused by SARSCoV-2, injury to the alveoli is thought to be the major cause of hypoxia and acute respiratory distress syndrome (ARDS)3.", [["alveoli", "ANATOMY", 171, 178], ["respiratory", "ANATOMY", 233, 244], ["injury to the alveoli", "DISEASE", 157, 178], ["hypoxia", "DISEASE", 215, 222], ["acute respiratory distress syndrome", "DISEASE", 227, 262], ["ARDS", "DISEASE", 264, 268], ["SARSCoV-2", "CELL", 146, 155], ["alveoli", "MULTI-TISSUE_STRUCTURE", 171, 178], ["NRB", "TREATMENT", 19, 22], ["injury", "PROBLEM", 157, 163], ["hypoxia", "PROBLEM", 215, 222], ["acute respiratory distress syndrome", "PROBLEM", 227, 262], ["ARDS)", "PROBLEM", 264, 269], ["injury", "OBSERVATION", 157, 163], ["alveoli", "ANATOMY", 171, 178], ["thought to be", "UNCERTAINTY", 182, 195], ["hypoxia", "OBSERVATION", 215, 222], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["respiratory distress", "OBSERVATION", 233, 253]]], ["Hypercoagulation appears to also be involved in the disease process, not merely sepsis related disseminated intravascular coagulation.", [["intravascular", "ANATOMY", 108, 121], ["Hypercoagulation", "DISEASE", 0, 16], ["sepsis", "DISEASE", 80, 86], ["intravascular coagulation", "DISEASE", 108, 133], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["Hypercoagulation", "PROBLEM", 0, 16], ["the disease process", "PROBLEM", 48, 67], ["merely sepsis", "PROBLEM", 73, 86], ["disseminated intravascular coagulation", "PROBLEM", 95, 133], ["appears to also be", "UNCERTAINTY", 17, 35], ["disease", "OBSERVATION", 52, 59], ["not merely", "UNCERTAINTY", 69, 79], ["sepsis", "OBSERVATION", 80, 86], ["disseminated", "OBSERVATION_MODIFIER", 95, 107], ["intravascular coagulation", "OBSERVATION", 108, 133]]], ["Coagulation markers, including D-dimer and fibrinogen, have been elevated in patients with COVID-19.", [["COVID-19", "CHEMICAL", 91, 99], ["D-dimer", "GENE_OR_GENE_PRODUCT", 31, 38], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 43, 53], ["patients", "ORGANISM", 77, 85], ["Coagulation markers", "PROTEIN", 0, 19], ["D-dimer", "PROTEIN", 31, 38], ["fibrinogen", "PROTEIN", 43, 53], ["patients", "SPECIES", 77, 85], ["Coagulation markers", "TEST", 0, 19], ["D-dimer", "TEST", 31, 38], ["fibrinogen", "TEST", 43, 53], ["elevated", "PROBLEM", 65, 73], ["COVID", "TEST", 91, 96], ["elevated", "OBSERVATION_MODIFIER", 65, 73]]], ["Implementation of anticoagulation has decreased morbidity and mortality2 and autopsies have found diffuse alveolar damage and microvascular thrombi in the lungs4.DiscussionThe exact mechanism of hypercoagulability is not yet understood.", [["alveolar", "ANATOMY", 106, 114], ["microvascular thrombi", "ANATOMY", 126, 147], ["lungs4", "ANATOMY", 155, 161], ["alveolar damage", "DISEASE", 106, 121], ["thrombi", "DISEASE", 140, 147], ["hypercoagulability", "DISEASE", 195, 213], ["alveolar", "TISSUE", 106, 114], ["microvascular thrombi", "PATHOLOGICAL_FORMATION", 126, 147], ["anticoagulation", "TREATMENT", 18, 33], ["decreased morbidity", "PROBLEM", 38, 57], ["autopsies", "TEST", 77, 86], ["diffuse alveolar damage", "PROBLEM", 98, 121], ["microvascular thrombi in the lungs4", "PROBLEM", 126, 161], ["hypercoagulability", "PROBLEM", 195, 213], ["decreased", "OBSERVATION_MODIFIER", 38, 47], ["morbidity", "OBSERVATION", 48, 57], ["diffuse", "OBSERVATION_MODIFIER", 98, 105], ["alveolar damage", "OBSERVATION", 106, 121], ["microvascular", "OBSERVATION_MODIFIER", 126, 139], ["thrombi", "OBSERVATION", 140, 147], ["hypercoagulability", "OBSERVATION", 195, 213]]], ["One postulation points to the functional receptor of the virus.", [["the virus", "PROBLEM", 53, 62], ["virus", "OBSERVATION", 57, 62]]], ["ACE2 is a counter regulatory component of the renin angiotensin system.", [["angiotensin", "CHEMICAL", 52, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["renin angiotensin", "GENE_OR_GENE_PRODUCT", 46, 63], ["ACE2", "PROTEIN", 0, 4], ["renin", "PROTEIN", 46, 51], ["ACE2", "TREATMENT", 0, 4], ["a counter regulatory component", "TREATMENT", 8, 38], ["the renin angiotensin system", "TREATMENT", 42, 70]]], ["Angiotensin II, which is cleaved by ACE2, is pro-inflammatory, pro-thrombotic, and vasoconstrictive.", [["Angiotensin II", "CHEMICAL", 0, 14], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["Angiotensin II", "PROTEIN", 0, 14], ["ACE2", "PROTEIN", 36, 40], ["Angiotensin II", "PROBLEM", 0, 14], ["pro-thrombotic", "PROBLEM", 63, 77], ["vasoconstrictive", "PROBLEM", 83, 99], ["pro-inflammatory", "OBSERVATION_MODIFIER", 45, 61], ["pro-thrombotic", "OBSERVATION", 63, 77], ["vasoconstrictive", "OBSERVATION_MODIFIER", 83, 99]]], ["ACE2 protects against excessive angiotensin II and some animal models showed COVID-19 was associated with a downregulation of the enzyme5.DiscussionPE, as well as diffuse pulmonary micro emboli, causes dead space ventilation by impairing appropriate alveolar perfusion.", [["pulmonary micro emboli", "ANATOMY", 171, 193], ["alveolar", "ANATOMY", 250, 258], ["angiotensin II", "CHEMICAL", 32, 46], ["pulmonary micro emboli", "DISEASE", 171, 193], ["COVID-19", "CHEMICAL", 77, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 32, 46], ["COVID-19", "GENE_OR_GENE_PRODUCT", 77, 85], ["enzyme5", "GENE_OR_GENE_PRODUCT", 130, 137], ["pulmonary", "ORGAN", 171, 180], ["alveolar", "MULTI-TISSUE_STRUCTURE", 250, 258], ["ACE2", "PROTEIN", 0, 4], ["angiotensin II", "PROTEIN", 32, 46], ["enzyme5", "PROTEIN", 130, 137], ["ACE2 protects", "TREATMENT", 0, 13], ["excessive angiotensin II", "TREATMENT", 22, 46], ["some animal models", "TEST", 51, 69], ["COVID", "TEST", 77, 82], ["the enzyme5", "TREATMENT", 126, 137], ["diffuse pulmonary micro emboli", "PROBLEM", 163, 193], ["dead space ventilation", "TREATMENT", 202, 224], ["impairing appropriate alveolar perfusion", "PROBLEM", 228, 268], ["diffuse", "OBSERVATION_MODIFIER", 163, 170], ["pulmonary", "ANATOMY", 171, 180], ["micro emboli", "OBSERVATION", 181, 193], ["dead space ventilation", "OBSERVATION", 202, 224], ["impairing", "OBSERVATION_MODIFIER", 228, 237], ["appropriate", "OBSERVATION_MODIFIER", 238, 249], ["alveolar perfusion", "OBSERVATION", 250, 268]]], ["The findings seen in our case were hypoxia, persistent hypercarbia in high minute ventilation, and normal lung compliance.", [["lung", "ANATOMY", 106, 110], ["hypoxia", "DISEASE", 35, 42], ["hypercarbia", "DISEASE", 55, 66], ["lung", "ORGAN", 106, 110], ["hypoxia", "PROBLEM", 35, 42], ["persistent hypercarbia", "PROBLEM", 44, 66], ["high minute ventilation", "TREATMENT", 70, 93], ["hypoxia", "OBSERVATION", 35, 42], ["persistent", "OBSERVATION_MODIFIER", 44, 54], ["hypercarbia", "OBSERVATION", 55, 66], ["high minute ventilation", "OBSERVATION", 70, 93], ["normal", "OBSERVATION", 99, 105], ["lung", "ANATOMY", 106, 110], ["compliance", "OBSERVATION", 111, 121]]], ["Although he was on systemic anticoagulation, it possibly had limited efficacy due to the high clot burden theorized in patients with moderate/severe COVID-19.", [["clot", "ANATOMY", 94, 98], ["clot", "ORGANISM_SUBSTANCE", 94, 98], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["systemic anticoagulation", "TREATMENT", 19, 43], ["the high clot burden", "PROBLEM", 85, 105], ["moderate/severe COVID", "PROBLEM", 133, 154], ["high", "OBSERVATION_MODIFIER", 89, 93], ["clot", "OBSERVATION", 94, 98], ["moderate", "OBSERVATION_MODIFIER", 133, 141], ["severe", "OBSERVATION_MODIFIER", 142, 148]]], ["In these cases, while there are no prospective studies evaluating the efficacy of tPA in COVID-19 due to its novelty, we hypothesize thrombolytic therapy dissolves current micro emboli while subsequent anticoagulant prevents re-clotting, improves gas exchange, lung perfusion, and oxygenation.DiscussionLung compliance in ARDS worsens as the severity increases.", [["lung", "ANATOMY", 261, 265], ["ARDS", "DISEASE", 322, 326], ["tPA", "GENE_OR_GENE_PRODUCT", 82, 85], ["lung", "ORGAN", 261, 265], ["prospective studies", "TEST", 35, 54], ["tPA", "TREATMENT", 82, 85], ["COVID", "TEST", 89, 94], ["thrombolytic therapy", "TREATMENT", 133, 153], ["current micro emboli", "PROBLEM", 164, 184], ["subsequent anticoagulant", "TREATMENT", 191, 215], ["lung perfusion", "TEST", 261, 275], ["ARDS", "PROBLEM", 322, 326], ["emboli", "OBSERVATION", 178, 184], ["lung", "ANATOMY", 261, 265], ["perfusion", "OBSERVATION", 266, 275], ["oxygenation", "OBSERVATION_MODIFIER", 281, 292], ["ARDS", "OBSERVATION", 322, 326]]], ["As the lung injury worsens leading to more edema, lung weight, and atelectasis, the volume of air in the lungs is displaced leading to dyspnea and hypoxia.", [["lung", "ANATOMY", 7, 11], ["edema", "ANATOMY", 43, 48], ["lung", "ANATOMY", 50, 54], ["lungs", "ANATOMY", 105, 110], ["lung injury", "DISEASE", 7, 18], ["edema", "DISEASE", 43, 48], ["atelectasis", "DISEASE", 67, 78], ["dyspnea", "DISEASE", 135, 142], ["hypoxia", "DISEASE", 147, 154], ["lung", "ORGAN", 7, 11], ["edema", "PATHOLOGICAL_FORMATION", 43, 48], ["lung", "ORGAN", 50, 54], ["lungs", "ORGAN", 105, 110], ["the lung injury", "PROBLEM", 3, 18], ["more edema", "PROBLEM", 38, 48], ["lung weight", "TEST", 50, 61], ["atelectasis", "PROBLEM", 67, 78], ["dyspnea", "PROBLEM", 135, 142], ["hypoxia", "PROBLEM", 147, 154], ["lung", "ANATOMY", 7, 11], ["injury", "OBSERVATION", 12, 18], ["more", "OBSERVATION_MODIFIER", 38, 42], ["edema", "OBSERVATION", 43, 48], ["lung", "ANATOMY", 50, 54], ["weight", "OBSERVATION", 55, 61], ["atelectasis", "OBSERVATION", 67, 78], ["volume", "OBSERVATION_MODIFIER", 84, 90], ["air", "OBSERVATION", 94, 97], ["lungs", "ANATOMY", 105, 110], ["displaced", "OBSERVATION", 114, 123], ["dyspnea", "OBSERVATION", 135, 142], ["hypoxia", "OBSERVATION", 147, 154]]], ["However, many patients with severe COVID-19 pneumonia have severe hypoxia with normal lung compliance and poor responsiveness to increasing levels of PEEP.", [["lung", "ANATOMY", 86, 90], ["COVID", "DISEASE", 35, 40], ["pneumonia", "DISEASE", 44, 53], ["hypoxia", "DISEASE", 66, 73], ["patients", "ORGANISM", 14, 22], ["lung", "ORGAN", 86, 90], ["patients", "SPECIES", 14, 22], ["severe COVID", "PROBLEM", 28, 40], ["pneumonia", "PROBLEM", 44, 53], ["severe hypoxia", "PROBLEM", 59, 73], ["poor responsiveness", "PROBLEM", 106, 125], ["PEEP", "TREATMENT", 150, 154], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["pneumonia", "OBSERVATION", 44, 53], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["hypoxia", "OBSERVATION", 66, 73], ["normal", "OBSERVATION", 79, 85], ["lung", "ANATOMY", 86, 90], ["compliance", "OBSERVATION", 91, 101], ["poor responsiveness", "OBSERVATION", 106, 125]]], ["These patients, much like the patient in this case, have pulmonary physiology more like dead space ventilation than shunting, suggestive of PE or pulmonary micro emboli.", [["pulmonary", "ANATOMY", 57, 66], ["pulmonary micro emboli", "ANATOMY", 146, 168], ["PE", "DISEASE", 140, 142], ["pulmonary micro emboli", "DISEASE", 146, 168], ["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 30, 37], ["pulmonary", "ORGAN", 57, 66], ["pulmonary", "ORGAN", 146, 155], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 30, 37], ["pulmonary physiology", "PROBLEM", 57, 77], ["dead space ventilation than shunting", "PROBLEM", 88, 124], ["PE", "PROBLEM", 140, 142], ["pulmonary micro emboli", "PROBLEM", 146, 168], ["pulmonary", "ANATOMY", 57, 66], ["space ventilation", "OBSERVATION", 93, 110], ["suggestive of", "UNCERTAINTY", 126, 139], ["PE", "OBSERVATION", 140, 142], ["pulmonary", "ANATOMY", 146, 155], ["micro emboli", "OBSERVATION", 156, 168]]], ["As they remain on the ventilator longer, some patients progress to a more traditional ARDS.DiscussionIn our case, there was a significant clinical improvement possibly because the disease had not progressed to advanced stages.", [["ARDS", "DISEASE", 86, 90], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the ventilator", "TREATMENT", 18, 32], ["a more traditional ARDS", "PROBLEM", 67, 90], ["the disease", "PROBLEM", 176, 187], ["ARDS", "OBSERVATION", 86, 90], ["disease", "OBSERVATION", 180, 187]]], ["He was the only patient in our unit who was intubated for less than 72 hours.", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["intubated", "TREATMENT", 44, 53]]], ["With the development of alveolar injury and pulmonary fibrosis, impaired gas exchange may be irreversible.", [["alveolar", "ANATOMY", 24, 32], ["pulmonary", "ANATOMY", 44, 53], ["alveolar injury", "DISEASE", 24, 39], ["fibrosis", "DISEASE", 54, 62], ["alveolar", "MULTI-TISSUE_STRUCTURE", 24, 32], ["pulmonary", "ORGAN", 44, 53], ["alveolar injury", "PROBLEM", 24, 39], ["pulmonary fibrosis", "PROBLEM", 44, 62], ["impaired gas exchange", "PROBLEM", 64, 85], ["alveolar", "ANATOMY_MODIFIER", 24, 32], ["injury", "OBSERVATION", 33, 39], ["pulmonary", "ANATOMY", 44, 53], ["fibrosis", "OBSERVATION", 54, 62], ["impaired", "OBSERVATION_MODIFIER", 64, 72], ["gas exchange", "OBSERVATION", 73, 85], ["may be", "UNCERTAINTY", 86, 92], ["irreversible", "OBSERVATION_MODIFIER", 93, 105]]], ["Wang et al discussed three cases where tPA transiently improved P/F ratios, but had little effect on their clinical condition.", [["tPA", "GENE_OR_GENE_PRODUCT", 39, 42], ["tPA", "TREATMENT", 39, 42], ["P/F ratios", "TEST", 64, 74]]], ["Important to note, all three patients were intubated and on vasopressor support alluding to late stages of COVID-196.", [["COVID-196", "CHEMICAL", 107, 116], ["COVID-196", "CHEMICAL", 107, 116], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["intubated", "TREATMENT", 43, 52], ["vasopressor support", "TREATMENT", 60, 79], ["COVID", "TEST", 107, 112]]], ["We credit the improvement in our patient to tPA because he continued to deteriorate while receiving other anticoagulants.", [["patient", "ORGANISM", 33, 40], ["tPA", "GENE_OR_GENE_PRODUCT", 44, 47], ["patient", "SPECIES", 33, 40], ["tPA", "TREATMENT", 44, 47], ["other anticoagulants", "TREATMENT", 100, 120], ["improvement", "OBSERVATION_MODIFIER", 14, 25]]], ["We postulate anticoagulants such as heparin or apixaban were ineffective because they block clot formation but do not induce clot breakdown7.", [["clot", "ANATOMY", 92, 96], ["clot", "ANATOMY", 125, 129], ["heparin", "CHEMICAL", 36, 43], ["apixaban", "CHEMICAL", 47, 55], ["apixaban", "CHEMICAL", 47, 55], ["heparin", "SIMPLE_CHEMICAL", 36, 43], ["apixaban", "SIMPLE_CHEMICAL", 47, 55], ["clot", "ORGANISM_SUBSTANCE", 92, 96], ["clot", "ORGANISM_SUBSTANCE", 125, 129], ["anticoagulants", "TREATMENT", 13, 27], ["heparin", "TREATMENT", 36, 43], ["apixaban", "TREATMENT", 47, 55], ["they block clot formation", "PROBLEM", 81, 106], ["clot breakdown7", "PROBLEM", 125, 140], ["clot", "OBSERVATION", 92, 96], ["clot", "OBSERVATION", 125, 129]]], ["However, we must acknowledge that he was on concomitant anticoagulants that may have affected his hospital course.DiscussionWhen considering tPA, risks and benefits must be appreciated.", [["tPA", "GENE_OR_GENE_PRODUCT", 141, 144], ["tPA", "PROTEIN", 141, 144], ["concomitant anticoagulants", "TREATMENT", 44, 70], ["tPA", "TREATMENT", 141, 144]]], ["The benefits have been noted in approved indications such as pulmonary embolism, ischemic stroke and ST elevation myocardial infarction.", [["pulmonary", "ANATOMY", 61, 70], ["myocardial", "ANATOMY", 114, 124], ["pulmonary embolism", "DISEASE", 61, 79], ["ischemic stroke", "DISEASE", 81, 96], ["myocardial infarction", "DISEASE", 114, 135], ["pulmonary", "ORGAN", 61, 70], ["myocardial", "MULTI-TISSUE_STRUCTURE", 114, 124], ["pulmonary embolism", "PROBLEM", 61, 79], ["ischemic stroke", "PROBLEM", 81, 96], ["ST elevation myocardial infarction", "PROBLEM", 101, 135], ["pulmonary", "ANATOMY", 61, 70], ["embolism", "OBSERVATION", 71, 79], ["ischemic", "OBSERVATION_MODIFIER", 81, 89], ["stroke", "OBSERVATION", 90, 96], ["myocardial", "ANATOMY", 114, 124], ["infarction", "OBSERVATION", 125, 135]]], ["Nonetheless, sometimes the risk outweighs the benefit in contraindicated states such as signs and symptoms of active bleeding8.", [["bleeding8", "DISEASE", 117, 126], ["symptoms", "PROBLEM", 98, 106], ["active bleeding8", "PROBLEM", 110, 126], ["active", "OBSERVATION_MODIFIER", 110, 116], ["bleeding8", "OBSERVATION", 117, 126]]], ["Bleeding or hemorrhage is a serious risk of thrombolytic therapy, as was seen in our case, and coagulation studies can guide its titration9.", [["Bleeding", "DISEASE", 0, 8], ["hemorrhage", "DISEASE", 12, 22], ["Bleeding", "PROBLEM", 0, 8], ["hemorrhage", "PROBLEM", 12, 22], ["thrombolytic therapy", "TREATMENT", 44, 64], ["coagulation studies", "TEST", 95, 114], ["hemorrhage", "OBSERVATION", 12, 22], ["serious", "OBSERVATION_MODIFIER", 28, 35], ["thrombolytic therapy", "OBSERVATION", 44, 64]]], ["Further investigation will help shed light on the legitimacy of thrombolytic therapy and its ideal timing, dosing, and criteria for inclusion.COISamit Ghia: no financial disclosures, no conflicts of interestCOIHimani Bhatt: financial disclosure \u2013 Clinical consultant for Neochord, LLC, no conflicts of interestCOIMichael Lazar: no financial disclosures, no conflicts of interest", [["Further investigation", "TEST", 0, 21], ["thrombolytic therapy", "TREATMENT", 64, 84], ["no", "UNCERTAINTY", 157, 159], ["LLC", "ANATOMY", 281, 284]]]]}